

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol for the FitMum study: Effects of structured supervised exercise training and motivational counselling during pregnancy on physical activity level and health of mother and offspring

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2020-043671 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 13-Aug-2020 |
| Complete List of Authors: | <p>Roland , Caroline ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Knudsen, Signe ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences</p> <p>Alomairah, Saud; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Saudi Electronic University, Department of Public Health</p> <p>Andersen , Anne ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Bendix , Jane ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Clausen , Tine ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics; University of Copenhagen Faculty of Health and Medical Sciences, Department of Clinical Medicine</p> <p>Molsted, Stig; Nordsjaellands Hospital, Department of Clinical Research</p> <p>Jensen, AK; University of Copenhagen, Department of Public Health; Nordsjaellands Hospital, Department of Clinical Research</p> <p>Teilmann , Grete ; Nordsjaellands Hospital, Department of Paediatrics</p> <p>Jespersen , Astrid ; University of Copenhagen Copenhagen Centre for Health Research in the Humanities, The Saxo Institute</p> <p>Larsen, Jakob ; Danmarks Tekniske Universitet, Department of Applied Mathematics and Computer Science</p> <p>Hall , Gerrit ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Rigshospitalet, Clinical Metabolomics Core Facility, Clinical Biochemistry</p> <p>Andersen, Emil ; University of Copenhagen Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research</p> <p>Barrès, Romain ; University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research</p> <p>Mortensen , Ole ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences</p> <p>Maindal, Helle; Aarhus Universitet, Department of Public Health; Steno Diabetes Center Copenhagen</p> <p>Tarnow , Lise ; Nordsjaellands Hospital, Department of Clinical Research; Steno Diabetes Center Copenhagen</p> <p>Løkkegaard, Ellen; Nordsjaellands Hospital, Department of Gynecology</p> |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | |
|-----------|---|
| | and Obstetrics; University of Copenhagen Faculty of Health and Medical Sciences, Department of Clinical Medicine Stalknecht, Bente; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences |
| Keywords: | OBSTETRICS, SPORTS MEDICINE, PUBLIC HEALTH, CLINICAL PHYSIOLOGY |
| | |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Protocol for the FitMum study: Effects of structured supervised exercise training and**
5 **motivational counselling during pregnancy on physical activity level and health of mother and**
6 **offspring**
7

8
9 **Caroline Borup Roland^{a, b}, *Signe de Place Knudsen^{b, a}, *Saud A Alomairah^{a, b, c}, Anne Dsane*
10 *Andersen^b, Jane Bendix^b, Tine D. Clausen^{b, d}, Stig Molsted^e, Andreas Kryger Jensen^{f, e}, Grete*
11 *Teilmann^g, Astrid Pernille Jespersen^h, Jakob Eg Larsenⁱ, Gerrit van Hall^{a, j}, Emil Andersen^k,*
12 *Romain Barrès^k, Ole Hartvig Mortensen^a, Helle Terkildsen Maindal^{l, m}, Lise Tarnow^{e, n}, Ellen*
13 *Løkkegaard^{b, d}, Bente Stallknecht^a*
14
15

16 ^a University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark

17 ^b Nordsjaellands Hospital, Department of Gynaecology and Obstetrics, Hillerod, Denmark

18 ^c Saudi Electronic University, College of Health Sciences, Public Health Department, Riyadh, Saudi
19 Arabia

20 ^d University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark

21 ^e Nordsjaellands Hospital, Department of Clinical Research, Hillerod, Denmark

22 ^f University of Copenhagen, Department of Public Health, Copenhagen, Denmark

23 ^g Nordsjaellands Hospital, Department of Paediatrics, Hillerod, Denmark

24 ^h University of Copenhagen, Copenhagen Centre for Health Research in the Humanities, The Saxo
25 Institute, Copenhagen, Denmark

26 ⁱ Technical University of Denmark, Department of Applied Mathematics and Computer Science,
27 Lyngby, Denmark

28 ^j Rigshospitalet, Clinical Metabolomics Core Facility, Clinical Biochemistry, Copenhagen, Denmark

29 ^k University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research,
30 Copenhagen, Denmark

31 ^l Aarhus University, Department of Public Health, Aarhus, Denmark

32 ^m Steno Diabetes Center Copenhagen, Gentofte, Denmark

33 ⁿ Steno Diabetes Center Sjaelland, Holbaek, Denmark

34
35
36
37
38 * Contributed equally
39
40
41
42

43 **Corresponding author:** Caroline Borup Roland, University of Copenhagen, Department of
44 Biomedical Sciences, Copenhagen, Denmark. E-mail: cba@sund.ku.dk
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

- **Introduction:** A physically active lifestyle during pregnancy improves maternal and offspring health, but can be difficult to follow. In Denmark, less than 40% of pregnant women meet the physical activity (PA) recommendations. The FitMum study aims to explore strategies to increase PA during pregnancy among women with low PA. It will evaluate the efficacy of two separate exercise regimens.
- **Objective:** To present the FitMum protocol, which evaluates the effects of structured supervised exercise training and motivational counselling supported by health technology on PA level during pregnancy.
- **Methods:** A single-site three-arm randomized controlled trial, which aims to recruit 220 healthy, pregnant women with gestational age (GA) no later than week 15 and whose PA level does not exceed one hour/week. Participants are randomized to either structured supervised exercise training consisting of three weekly exercise sessions, motivational counselling supported by health technology, or a control group receiving standard care. The interventions take place from randomization until delivery.
- **Primary outcome:** Min/week of moderate-to-vigorous-intensity PA as determined by a commercial activity tracker, collected from randomization until GA of 28 weeks and 6 days.
- **Secondary outcome:** Gestational weight gain.
- **Additional outcomes:** Complementary measures of PA; clinical and psychological health parameters in participant, partner, and offspring; analyses of blood, placenta and breast milk samples; process evaluation of interventions; personal understandings of PA.
- **Conclusion:** The study will provide valuable guidance and scientific evidence about the efficacy and applicability of two different PA regimens during pregnancy and will provide novel insight into the potential health benefits for the mother and for the offspring.
- **Strengths and limitations of this study:**
 - The efficacy of structured supervised exercise training and motivational counselling supported by health technology to improve physical activity and weight gain of pregnant women is compared in a randomized controlled trial.
 - The trial involves complex interventions and is held in one site only, so generalizability and fidelity might be a concern. Yet, as one of the additional outcomes, a process evaluation is conducted alongside the trial to explore how the interventions are carried out and adapted.
 - The study is comprehensive and multidisciplinary in its design. Many different methodologies are used and both mother, partner and offspring are studied.
 - Activity trackers can increase physical activity level and are feasible tools in everyday life, but commercial activity trackers have limited validity for quantification of physical activity.

- Physical activity is extensively measured using three different methods: commercial activity trackers, gold standard doubly labelled water, and the validated Pregnancy Physical Activity Questionnaire.

Trial registration: ClinicalTrials.gov (# NCT03679130). Registered September 20, 2018.

Protocol version: This paper was written per the study protocol version 8 dated August 28, 2019.

For peer review only

Introduction

Although the health effects of physical activity (PA) are widely acknowledged, the means of how to implement and maintain PA in everyday life are lacking (1). Pregnancy can be regarded as a window of opportunity to implement good habits of PA as pregnant women are in regular contact with health professionals and likely motivated to adopt healthy behaviours, as illustrated by reduced alcohol consumption and smoking cessation (2–4). On the other hand, pregnancy can be conceived as an opportunity to be exempt from demands about fitness and bodily ideals, or be experienced as a problematic and troublesome time with fatigue and discomfort (5,6). Moreover, pregnancy is a short period when it comes to change of habits (6), and that may affect the motivations and challenges to be physically active. Furthermore, differences in work status, social relations, the family situation, as well as material and structural conditions may contribute to the implementation of PA (7).

Insufficient PA during pregnancy is a global problem (8–12). It is a significant public health issue, as increasing evidence suggests that lifestyle during pregnancy influences health in the mother and her offspring (4,13). Regular PA during pregnancy promotes clinical and metabolic health in mother and offspring and reduces the number of complications during pregnancy and delivery (14–19). PA reduces gestational weight gain (20–26), the risk of gestational diabetes mellitus (27–32), the intensity of low back pain (33), the risk of caesarean delivery (22,29,34–37) and improves maternal body composition (38). Also, a physically active pregnancy improves the health of the offspring by normalizing birth weight (22), reducing the risk of preterm delivery (39,40), improving neonatal body composition (41,42), as well as placental function (43,44), resulting in optimized intrauterine growth conditions.

The Danish Health Authorities recommend that healthy pregnant women are physically active for at least 30 min/day at moderate intensity (45), but only 38% of Danish pregnant women achieve the recommended level (46). Several barriers to PA during pregnancy are addressed in the literature (47), including anxiety about over-doing exercise, low motivation to adopt an active lifestyle during pregnancy, changing energy levels throughout the pregnancy, and lack of time to be physically active (48). The latest recommendations on lifestyle interventions during pregnancy support individualized advice about how to increase the PA level rather than a generic approach (6), as pregnant women prefer personalized information (49). Consequently, policymakers, healthcare professionals, and pregnant women urge for evidence-based guidance on how to implement PA in everyday life during pregnancy safely and effectively, and with approaches that meet the needs, preferences, and choices of the pregnant woman.

During the past decades, many PA intervention studies in pregnant women have been conducted on overweight and obese populations (23,24,26,28,50–57) as well as in healthy normal-weight pregnant women (20,21,32,33,58–61). Still, none of these has focused primarily on investigating the effect of the exercise interventions on actual PA level in pregnant women nor used novel objective methods to measure actual PA levels. Structured supervised exercise training or motivational counselling have been applied separately in pregnant women (20,21,23,24,26,28,32,33,50–55,58–63), but the relative

1
2
3
4 efficacy has not been compared, which hampers the evidence-based implementation of effective
5 exercise programs into everyday life.
6

7 **Objective**

8 This paper describes the protocol for the FitMum study, which is centred around a randomized
9 controlled trial (RCT). The FitMum RCT aims to evaluate the effects of structured supervised exercise
10 training (EXE) and motivational counselling supported by health technology (MOT) compared to
11 standard care (CON) on PA level and body weight gain during pregnancy. Additional aims are to
12 investigate the effects of EXE and MOT on clinical and metabolic health parameters in mother and
13 offspring. We will also explore how the FitMum exercise programs are carried out and adopted by
14 conducting a process evaluation. In addition, we explore the personal attribution of meaning to the
15 experiences and practices of PA among the participants. Furthermore, we investigate how social,
16 structural, and cultural factors facilitate or hinder the successful implementation of exercise during
17 pregnancy.
18
19
20
21
22

23 **Methods**

24 **Study design**

25 The FitMum RCT is a single-site, three-arm trial.
26

27 **Setting**

28 The study is carried out at the Department of Gynaecology and Obstetrics, Nordsjaellands Hospital
29 (NOH), Hillerod, in the Capital Region of Denmark. NOH is a public hospital and participation in
30 FitMum is free of charge.
31
32

33 **Participants**

34 220 healthy, pregnant women will be included. Inclusion criteria are an obtained written informed
35 consent, maternal age of 18 years or older, gestational age (GA) of max. 15 weeks, ultrasonic
36 confirmed viable intrauterine pregnancy, body mass index of 18.5-45 kg/m² and body weight <150 kg
37 (pre-pregnancy weight or first measured weight in pregnancy), ability to wear a wrist-worn activity
38 tracker 24/7 until one year postpartum and having a smartphone. Exclusion criteria are structured
39 exercise at moderate-to-vigorous intensity for more than one hour/week during early pregnancy,
40 previous preterm delivery, obstetric or medical complications, multiple pregnancies, non-Danish
41 speaking, or alcohol or drug abuse.
42
43
44
45

46 **Recruitment and inclusion**

47 Participants are recruited 1) *via* booking confirmation of a first-trimester scan, 2) at face-to-face
48 meetings during the first-trimester scan, and 3) through posters, flyers, and social media. Before
49 inclusion, interested women answer an online one-page pre-screening questionnaire. Eligible
50 participants and their partners are invited to the first visit at NOH as soon as possible and not later than
51 GA of 14 weeks and 6 days. At visit 1, the woman is verbally informed about the study and screened
52 according to in- and exclusion criteria. Women who have not had a first-trimester scan are vaginally
53 scanned to confirm a singleton, viable intrauterine pregnancy. All eligible women are included and
54
55
56
57
58
59
60

1
2
3
4 written informed consent obtained. Written informed consent is also obtained from the biological father
5 or other holders of custody as biological samples are collected from the offspring and, if known, from
6 the biological father. A short semi-structured interview with the participant is recorded. The interview
7 provides knowledge of the participant's thoughts on participating in a research project, knowledge of
8 prior and current PA level as well as experiences with health technologies. After inclusion,
9 anthropometric and demographic information and a blood sample are collected.
10
11

12
13 At the end of visit 1, the participant receives a commercial activity tracker, Garmin Vivosport. The
14 participant is instructed to wear the tracker continuously 24/7 from the one-week baseline period until
15 one year postpartum, except during charging. The activity tracker is water-resistant and determines the
16 frequency, duration, and intensity of activity periods on a minute-to-minute basis. The data from the
17 activity tracker are wirelessly synced to the associated app, Garmin Connect, provided by Garmin
18 International, and the research platform Fitabase (Small Steps Labs LLC), through which the compliance
19 of wearing and synchronizing the data from the tracker are continuously monitored during the study.
20
21

22 **Baseline period and randomization**

23 After inclusion, the baseline PA level of the participant is measured by the activity tracker for one
24 week. After the baseline period, participants are randomized into the CON, EXE, or MOT groups
25 (Figure 1). The target number of participants randomized to each group is 44, 88, and 88, respectively,
26 to have more participants in the intervention groups. Randomization is performed via a numbered
27 randomization list administered through the database Research Electronic Data Capture (REDCap), and
28 the investigators are blinded to the procedure. Blinding of participants is considered impossible due to
29 the inherent content of the exercise interventions. The participant is informed about the assigned group
30 by email, and participants in EXE and MOT receive written information containing guidelines from the
31 Danish Health Authorities about PA during pregnancy.
32
33

34 **Patient and public involvement**

35
36 Template for Intervention Description and Replication (64) was used as inspiration for the development
37 and description of the study. As a part of the development phase, stakeholders in the field were
38 involved in discussions and sharing of knowledge. Additionally, 27 semi-structured interviews with
39 Danish pregnant women, midwives, and obstetricians were performed to explore the feasibility of such
40 study as well as the motivational factors and barriers to PA during pregnancy. Participants are not
41 directly involved in recruitment and conduct of the study, but at process evaluation is carried out and
42 personal understandings of the participants are obtained via interviews (see below). The insights from
43 the study will be shared with the participants at an information meeting after the end of the study.
44
45
46
47

48 **Interventions**

49 **Standard care at the hospital**

50 All three groups are offered the standard care that applies to women giving birth at NOH. It consists of
51 three appointments with their general practitioner (GA weeks 6-10, 25 and 32), five to six midwife
52
53
54
55
56

1
2
3
4 consultations (GA weeks 14-17, 29, 36, 38, 40 and if still pregnant around week 41 as well) and
5 ultrasonic scans at GA weeks 12 and 20.
6

7 8 **Standard care control group (CON)**

9 Participants in CON wear an activity tracker to determine the activity level. The face of the tracker
10 looks like a normal watch showing only time and battery life.
11

12 13 **Structured supervised exercise training intervention (EXE)**

14 The targeted PA level for all participants in EXE and MOT is at least 30 min/day at a moderate
15 intensity as recommended to healthy pregnant women (6). In EXE, exercise training is in teams and
16 supervised by health professionals (exercise physiologists, physiotherapists, public health scientists). It
17 consists of three weekly one-hour exercise sessions at moderate intensity, including two exercise
18 sessions in a gym and one in a swimming pool. The gym sessions consist of a combination of aerobic
19 and resistance training with 30 min stationary bike training (a combination of hill climbing and high
20 cadence intervals) and 30 min of e.g. elastic bands, exercise balls, mats, dumbbells or own body
21 weight. In the swimming pool, participants do 15 min of swimming and 45 min of water exercises with
22 plates, balls, dumbbells or own body weight. Moderate intensity during training sessions is assessed
23 using both heart rate monitoring of 65-80% of age-predicted maximal heart rate (from the activity
24 tracker) and perceived exertion in the range of 12-14 on Borg's conventional 6-20-point scale (65), as
25 recommended by the American College of Obstetricians and Gynaecologists (14). If a participant
26 experiences any pain or needs to slow down, the content of exercise sessions is adjusted individually
27 accordingly. Exercise sessions are offered at seven different times per week, and participants are
28 recommended to sign up for three of these sessions. The sessions are held early mornings or late
29 afternoons all weekdays, and before noon on Fridays and Saturdays.
30
31
32
33
34
35

36 37 **Motivational counselling supported by health technology (MOT)**

38 This intervention comprises four individual and three group counselling sessions as well as weekly
39 SMS-reminders. The overall focus of both the individual and group counselling sessions is built based
40 on what already motivates the participants to increase or maintain their PA level. The motivation
41 technique applied is inspired by motivational interviewing (66), self-determination theory (67), and
42 behaviour change techniques (68).
43
44

45 All four *individual sessions* last one hour and are led by professional health counsellors (exercise
46 physiologists, physiotherapists, public health scientists). The sessions aim to discuss the participant's
47 barriers, wishes, needs, knowledge, and former PA experiences to identify individual characteristics
48 and motivation towards a more physically active lifestyle. Aside from measuring the PA level, the
49 activity trackers are also used as an intervention element to motivate the participants to increase their
50 PA levels (69). During the individual sessions, feedback on recent PA performances is provided based
51 on activity data acquired from the activity tracker, to give the participants insight into their PA level.
52 The participants will, with guidance from the counsellor, set their own activity goals and make an
53
54
55
56
57
58
59
60

1
2
3
4 individual action plan to increase the PA level, which may have a motivating effect on PA behaviour
5 (69,70). Individual sessions are scheduled during the daytime but as appropriate for the participant as
6 possible.
7

8
9 The first *group session* lasts one hour and aims to inform the participants about guidelines for PA,
10 benefits associated with PA during pregnancy, and possible ways to increase PA during pregnancy. In
11 the following two two-hour group sessions, the interaction between the participants is used to create
12 meaningful group processes such as support, experience exchange, reflection, learning, and
13 development. These sessions focus on discussion of relevant topics concerning PA during pregnancy,
14 and the counsellor acts as a facilitator through the session, with the topics of conversation chosen by
15 the participants. Issues like postpartum PA, the pelvic floor, uterine contractions, diastasis recti, and
16 myths about pregnancy PA are discussed. Group sessions are held late afternoons, or before noon for
17 those being on maternity leave.
18
19
20

21 The weekly SMS-reminders have supportive and motivating content and are used to encourage the
22 participants to achieve a moderate PA level. The texts are chosen based on every participant's PA level
23 during the last week measured by the activity tracker. One example of the text: "You have been
24 exercising regularly for an extended period of time. Well done. Good habits make it easier for you to
25 continue as your belly gets bigger and heavier."
26
27

28 **Outcome measures**

29 The data collection procedures are illustrated in Table 1.
30

31 **Primary outcome: physical activity level**

32
33 The primary outcome of FitMum RCT is min/week of moderate-to-vigorous-intensity PA measured
34 continuously from randomization to GA of 28 weeks and 6 days as determined by a wrist-worn activity
35 tracker, Garmin Vivosport, with built-in heart rate monitor and accelerometer.
36
37

38 **Secondary outcome: gestational weight gain**

39 Body weight of the participant before pregnancy is self-reported. Body weight during pregnancy is
40 measured five times from inclusion until delivery on the same scale (Seca 799) with the participant in
41 light clothes and without shoes.
42
43

44 **Additional outcomes**

45 *Complementary measures of physical activity*

46
47 Complementary measures of PA are obtained by the Danish version of 'Pregnancy Physical Activity
48 Questionnaire' (PPAQ) (71) named PPAQ-DK, and by the doubly labelled water technique (72). PPAQ
49 is a semi-quantitative and subjective instrument, which has been validated (71) and is considered one of
50 the most valid and reliable questionnaires for assessment of PA level in pregnant women (73). Our
51 research group has translated PPAQ into Danish and validated it in a Danish pregnant population
52 (manuscript in review).
53
54
55

1
2
3
4 The doubly labelled water technique is the ‘gold standard’ technique to measure free-living energy
5 expenditure objectively, and is safe, even for pregnant women, as it relies on stable, non-radioactive
6 isotopes (74–77). The participant is administered a glass of water for oral intake containing 0.1 g of
7 99.98 % $^2\text{H}_2\text{O}$ and 1.6 g of 10% ^{18}O per kg body weight. In total, five post-dose urine samples are
8 collected in the morning (not the first urine void of the day); on the day after oral water dosage, and
9 after four, seven, 11, and 14 days. The urine samples are stored in the participant’s freezer and later at
10 -80 °C.
11
12
13

14 In addition, PA of the participant is determined from GA week 29 until delivery and in the first year
15 postpartum by the activity tracker. The measures of PA include active calories, active time, steps, heart
16 rate, moderate- and vigorous-intensity activity, floors climbed, MET-min/week, and type of activity,
17 which is recognized automatically by the tracker.
18
19

20 *Clinical and psychological health parameters in participant, partner, and offspring*

21 A variety of clinical and psychological health parameters are obtained from the participant, her partner,
22 and her offspring. *Clinical data* regarding pregnancy, delivery, and neonatal outcomes are collected
23 from medical records. *Health-related quality of life* is determined in the participant by the Danish
24 version of the Medical Outcomes Study Short Form 36 (SF-36) (78,79), which has also been validated
25 in pregnancy (80). *Exercise self-efficacy* is determined by the Danish version of the Pregnancy Exercise
26 Self-Efficacy Scale (P-ESES) (81). P-ESES has been translated into Danish and validated in a Danish
27 pregnant population by our research group (82). *PA motivation* is determined by the Danish version of
28 the Behavioural Regulation in Exercise Questionnaire (BREQ-2) (83–85), which is the most widely
29 used measure of the continuum of behavioural regulation in exercise psychology research. *Sleep*
30 *quantity and quality* are assessed in the participant by the activity tracker and by the Danish version of
31 the self-administered questionnaire Pittsburgh Sleep Quality Index (PSQI) (86,87). The PSQI is
32 considered a valid and reliable tool to assess sleep metrics among pregnant women (88). In addition, a
33 validation of activity trackers to measure sleep will be conducted using polysomnography in a sub-
34 group of women already participating in the FitMum study. *Sick leave and pelvic and low back pain* are
35 registered by asking the participant whether she has been absent from work/study and on sick leave
36 during her pregnancy and whether she has experienced pelvic and low back pain before and during her
37 pregnancy. *Maternal body composition* is determined from total body water measured by doubly
38 labelled water technique and by a postpartum Dual-energy X-ray absorptiometry (DXA) scan.
39 *Offspring growth*: Head circumference, length, and weight is measured at birth and at general
40 practitioners at five weeks, five months, and 12 months postpartum. Participants receive an electronic
41 questionnaire and fill out the anthropometric data along with information on offspring dietary habits
42 and vaccine-status. *Parental mental wellbeing* is assessed 6-8 weeks after birth. Both parents or holders
43 of custody receive a questionnaire consisting of the Edinburgh Postnatal Depression Score, and
44 Gotland Depression Scale that combined is a screening tool for postnatal depression (89–92) used in
45 the Danish postnatal care. *Psychomotor development of the offspring* is assessed by the validated Ages
46 and Stages Questionnaire 3 (ASQ-3), which is administered electronically to participants 12 months
47
48
49
50
51
52
53
54
55
56

1
2
3
4 after the due date. ASQ-3 pinpoints developmental progress in the fields of communication, gross
5 motor, fine motor, problem-solving, and personal-social skills. The administration of ASQ-3 relative to
6 due and not to birth date aims to correct for variance in cognitive and motor skills due to premature
7 birth. *Offspring physical activity* is assessed for seven days by an infant activity tracker (Actigraph
8 GT3X+) 12 months after the due date. The tracker detects level, intensity, and pattern of physical
9 activity.
10
11

12 *Analyses of blood, placenta and breast milk samples*

13
14 *Plasma metabolites and hormones* are assessed in maternal and paternal venous blood. The blood
15 samples will be analysed for concentrations of glucose, cholesterol (total, high and low density),
16 triglyceride, insulin, free fatty acids, amino acids, interleukin-6, and C-reactive protein. Venous blood
17 is obtained from the umbilical cord within 30 min after delivery of the placenta. The blood will be
18 analysed for concentrations of glucose, cholesterol (total, high and low density), triglyceride, insulin, c-
19 peptide, free fatty acids, amino acids, adiponectin, and leptin. Furthermore, epigenetic profiling at the
20 level of *DNA methylation* will be performed in maternal, paternal, and umbilical cord blood
21 mononuclear cells. Bioinformatic comparison of DNA methylomes from parents and offspring will
22 infer on the DNA methylation marks that are modulated by maternal exercise and transmitted to the
23 offspring. Information on DNA methylomes from each parent will allow us to distinguish between
24 maternally and paternally transmitted epigenetic profiles to the offspring. Principal component analyses
25 will be used to identify the specific metabolic or anthropometric features of the mother that are
26 associated with a specific DNA methylation footprint transmitted to the offspring. *Placental function* is
27 assessed from samples taken within 30 min after delivery of the placenta. The samples are immediately
28 frozen on dry ice and stored at -80 °C. Analyses will include RNA-seq, non-targeted metabolomics,
29 RT-qPCR, Western blot, histology, and immunohistochemistry. *Breast milk* is obtained from a single
30 feed at the day of visit 5 and stored at -80 °C for later metabolomic and lipidomic analyses.
31
32
33
34
35
36

37 *Process evaluation of interventions*

38
39 A process evaluation is made using quantitative and qualitative methods to provide insight into
40 mechanisms through which interventions bring about change, assess fidelity and quality of
41 implementation, clarify causal mechanisms, and identify contextual factors associated with variations
42 in outcomes (93–95). Integrating process evaluations alongside outcome data are recommended by the
43 UK Medical Research Council guidelines to develop and evaluate complex interventions to improve
44 the interpretation of the outcomes, design more effective interventions, and apply them appropriately
45 across groups and settings by understanding the implementation and functioning of interventions in a
46 given context (94,96). The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and
47 Maintenance) framework is used to improve reporting on key issues related to the implementation and
48 external validity of FitMum RCT (97).
49
50
51
52
53
54
55
56

Personal understandings of physical activity

The qualitative dataset is comprised of 220 short standardised screening interviews, 30 semi-structured interviews, 70 observations, five sets of auto-ethnographies, visual material, as well as drop-out and follow-up interviews. This sub-project will explore the physical and mental health and wellbeing of the participants, their social relations, PA levels, and their experience of pregnancy to identify the challenges and barriers of PA during pregnancy. Personal understandings of PA in the everyday life of the participants are determined at inclusion, GA week 34, and one year postpartum, in approximately ten participants from each of the three study groups.

Changes during the COVID-19 pandemic

During the COVID-19 pandemic (in Denmark from March 11th 2020), all interventions and visits (except the birth) are converted into online versions using Zoom Cloud Meetings or telephone. In EXE, the swimming pool sessions are cancelled, and all sessions are land exercise sessions consisting of 30 min of aerobic exercise where the participants exercise on their own (e.g. biking, power-walking, dancing, aerobics) followed by 30 min of supervised online group resistance training. All individual and group MOT sessions are held online.

As much data as possible is collected during the pandemic, but some clinical data have not been possible to obtain due to limitations on non-urgent visits to the hospital. No blood samples are obtained at the virtual ‘visits’, the women are weighed at home, and symphysis-fundal height measurements are not obtained. No doubly labelled water is administered at the virtual ‘visit’ 2. The women’s body weight at visit 4 is noted by the midwives on the day of giving birth, but biological samples are not collected. No DXA-scans or breast milk samples are collected at ‘visit’ 5.

Data management and analysis

Data management

The activity tracker data are collected by Fitabase that regularly backs up the data. A participant who does not synchronize the tracker for seven days or more is reminded by email, text message, or phone call. All tracker data are exported from Fitabase to R (98) for data analysis. Tracker data are utilized to calculate the non-wear time; a week is included in the analysis if the week has four or more days with complete data. A day that has six hours or more of non-wear time is excluded and considered a missing day. An electronic case report form (e-CRF) is utilized to collect all clinical data related to the trial. Data are stored in coded form according to the rules of the Danish Data Protection Agency. Personal data processing is complied with, concerning the Act on Processing of Personal Data. The e-CRF is completed by the investigators at the time of the participant’s visits at NOH so that it always reflects the latest observations for the participant. Data will be stored for 25 years, after which they will be transferred to the Danish National Archives “Rigsarkivet” in an anonymized format.

Sample size

FitMum RCT has been powered to detect an overall significant difference in the primary outcome between the three groups as well as a significant difference between the two intervention groups (EXE

1
2
3
4 vs. MOT) with average activity levels of 60 (CON), 210 (EXE) and 150 (MOT) min/week. The
5 standard deviation was set at 116 min/week and based on the results from Oostdam et al. (51). The
6 required sample size is determined to obtain a power of 80% with a family-wise significance level of
7 5%. The sample size calculation showed that the required number of participants is 35 in CON and 70
8 in each of the two intervention groups due to the randomization ratio of 1:2:2 to CON, EXE, and MOT,
9 respectively. Based on an expected lost-to-follow-up rate of 20%, as seen in similar exercise studies in
10 pregnant women (28,32,33,51), we plan to include 44 participants in CON and 88 participants in each
11 of the two intervention groups, making a total of 220 participants.
12
13
14

15 **Statistical methods**

16 Data analyses of both primary and secondary outcomes will be performed using intention-to-treat
17 analyses. In addition, a dose-response model will be estimated to quantify the relationship between
18 adherence to the intervention (proportion of attendances in the planned EXE and MOT sessions,
19 respectively) and the activity level. Moreover, analyses describing associations between the level of
20 physical activity, as measured by the activity tracker, and the secondary and additional outcomes will
21 be performed. Baseline data will be reported as averages and standard deviations (medians and
22 interquartile ranges) or frequencies and proportions as appropriate. No interim analyses will be
23 performed on the primary and secondary outcomes. The analysis of the primary outcome will be
24 performed using a linear model with the randomization group as a categorical covariate and with
25 adjustment for baseline PA level. Hypothesis tests will be performed using likelihood ratio tests.
26 Statistical analysis will be carried out using R (98). Analyses of the primary outcome will be performed
27 by a statistician blinded from the intervention allocations. Investigators will perform analyses of
28 baseline data and secondary and additional outcomes under the supervision of a statistician.
29
30
31
32
33
34

35 **Trial status and dissemination**

36 The recruitment of participants started in September 2018. Data collection of the primary outcome is
37 expected to complete early 2021. Full data collection is expected to be complete in 2022.
38

39 The FitMum study will provide evidence-based knowledge that can contribute to improving national
40 and international recommendations of PA during pregnancy and to new, effective, and simple guidance
41 to implement health technology-supported exercise programs to pregnant women. Based on the results
42 and the process evaluation, the knowledge and tools from the FitMum study can be transformed into
43 initiatives in municipalities and hospitals to improve the health and quality of life for both mother and
44 child, and for preventing the development of lifestyle-related diseases across generations.
45
46
47

48 Findings will be submitted for publication in peer-reviewed scientific journals and disseminated at
49 national and international conferences. Further, results will be disseminated to the general public in
50 relevant media and to health professionals via science theatre performances.
51

52 **Ethical aspects**

53 The FitMum study adheres to the principles of the Helsinki declaration. The study is approved by the
54
55
56

1
2
3
4 Danish National Committee on Health Research Ethics (# H-18011067) and the Danish Data Protection
5 Agency (# VD-2018-336).
6

7 All participants consent in written form before inclusion and are informed that participation in the
8 FitMum study is voluntary. Participants are informed that they may withdraw from the study at any
9 time, and that withdrawal of consent will not affect any subsequent pregnancy and delivery process at
10 NOH. The participant has time to ask questions and is allowed 24 hours to deliberate on study
11 participation before the obtainment of written informed consent.
12
13

14 FitMum RCT is designed based on recommendations of appropriate PA during pregnancy
15 (14,45,99,100), and although there are anatomic and physiological changes during pregnancy, PA
16 during an uncomplicated pregnancy is safe (14,22,29,40,60,101–104). All information about adverse
17 events and serious adverse events are documented consecutively and will be reported. A participant
18 with a serious obstetric or medical complication will be discontinued from interventions.
19
20
21

22 Discussion

23 The FitMum study aims to evaluate the effects of structured supervised exercise training and
24 motivational counselling supported by health technology on PA level during pregnancy to generate
25 evidence about *how* to implement PA in healthy pregnant women's everyday life. Previous studies
26 have investigated the effect of different lifestyle interventions in normal weight (23,24,26,28,50–57),
27 overweight, and obese pregnant women (20,21,32,33,58–61) on various health outcomes. However,
28 neither has focused primarily on investigating the effect of PA interventions on actual PA level
29 determined by novel objective methods. In addition, the FitMum study compares the effect of two
30 different PA interventions to explore strategies to implement PA programs into pregnant women's
31 everyday life. Moreover, offspring of FitMum participants is studied for one year after birth whereby
32 knowledge on the effect PA during pregnancy on offspring health is obtained.
33
34
35
36

37 Consumer-based wearable activity trackers tend to increase the PA level when they are used as an
38 intervention tool or as part of an intervention (105). Activity trackers are often relatively light in
39 weight, comfortable to wear, and rechargeable (106). In addition, using an activity tracker to measure
40 PA during pregnancy is recommended (107), and it is feasible and has a reasonable compliance rate
41 during pregnancy and after giving birth (108). However, there are some challenges and limitations of
42 using activity trackers in a long intervention study. Firstly, the participants must recharge the device
43 and synchronize their data approximately once weekly, which puts a burden on the participants and
44 challenge the adherence and compliance. Secondly, we cannot control the interaction of CON
45 participants with the tracker. Thirdly, the main goal for the tracker's design is a comfortable wear, yet
46 long-time wearing may cause skin irritation and discomfort (109). Moreover, the unavailability of raw
47 data and algorithms used by the manufacturer creates a limitation in the validation of PA metrics (106).
48 Therefore, measuring PA by a variety of methods, and performing a comparison with a gold standard
49 method, the doubly labelled water technique, will be conducted to obtain comprehensive measures of
50 PA behaviours in FitMum participants.
51
52
53
54
55
56

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

We would like to thank the technical staff, especially Susanne Månsson, from the Clinical Research Unit, Department of Research, NOH, for their contribution to planning the practical work involved in the collection of data.

Funding

The FitMum study has been financially supported by the Independent Research Fund Denmark (8020-00353B), TrygFonden (128509), Copenhagen Center for Health Technology (061017), Beckett-Fonden (17-2-0883), Aase and Ejnar Danielsens Fond (10-002052), and Familien Hede Nielsens Fond (2017-1142). Basic funding was donated by NOH and University of Copenhagen.

Authors' contribution

BS initiated the FitMum study together with LT and is the principal investigator of FitMum RCT. EL is the clinical trial manager. CBR, SdPK and BS led the protocol development with contribution from SA, ADA, JB, TDC, SM, AKJ, GT, APJ, JEL, GvH, EA, RB, OHM, HTM, LT, and EL. CBR, SdPK, SA, ADA, JB, TDC, SM, EL and BS constitute the clinical core group that guides the practical performance of FitMum RCT. CBR, SdPK and ADA are conducting intervention activities together with research assistants and master students. CBR, SdPK, SA and ADA will perform most of the data analysis along with AKJ. Analyses of the primary outcome will be performed by AKJ. All authors read, contributed to and approved the final version of the manuscript.

References

1. Craike M, Hill B, Gaskin CJ, Skouteris H. Interventions to improve physical activity during pregnancy: a systematic review on issues of internal and external validity using the RE-AIM framework. *BJOG An Int J Obstet Gynaecol*. 2017;124(4):573–83.
2. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. Interventions to reduce or prevent obesity in pregnant women: A systematic review. *Health Technol Assess (Rockv)*. 2012;16(31):1–8.
3. World Health Organisation (WHO). Good Maternal Nutrition. The best start in life. 2016;
4. Adamo KB, Ferraro ZM, Brett KE. Can we modify the intrauterine environment to halt the intergenerational cycle of obesity? *Int J Environ Res Public Health*. 2012;9(4):1263–307.
5. Jelsma JGM, Van Leeuwen KM, Oostdam N, Bunn C, Simmons D, Desoye G, et al. Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study. *J Pregnancy*. 2016;1–11.
6. Hill B, McPhie S, Moran LJ, Harrison P, Huang TTK, Teede H, et al. Lifestyle intervention to prevent obesity during pregnancy: Implications and recommendations for research and

- 1
2
3
4 implementation. *Midwifery*. 2017;49(May 2016):13–8.
5
6 7. Bønnelycke J, Sandholdt CT, Jespersen AP. Household collectives: resituating health promotion
7 and physical activity. *Sociol Heal Illn*. 2019;41(3):533–48.
8
9 8. Borodulin K, Evenson KR, Herring AH. Physical activity patterns during pregnancy through
10 postpartum. *BMC Womens Health*. 2009;9(1):32.
11
12 9. Santo EC, Forbes PW, Oken E, Belfort MB. Determinants of physical activity frequency and
13 provider advice during pregnancy. 2017;1–11.
14
15 10. Hegaard HK, Damm P, Hedegaard M, Henriksen TB, Ottesen B, Dykes AK, et al. Sports and
16 leisure time physical activity during pregnancy in nulliparous women. *Matern Child Health J*.
17 2011;15(6):806–13.
18
19 11. Owe KM, Nystad W, Bø K. Correlates of regular exercise during pregnancy: The Norwegian
20 Mother and Child Cohort Study. *Scand J Med Sci Sport*. 2009;19(5):637–45.
21
22 12. Richardsen KR, Falk RS, Jenum AK, Mørkrid K, Martinsen EW, Ommundsen Y, et al.
23 Predicting who fails to meet the physical activity guideline in pregnancy: A prospective study of
24 objectively recorded physical activity in a population-based multi-ethnic cohort. *BMC*
25 *Pregnancy Childbirth*. 2016;16(1):1–11.
26
27 13. Barrès R, Zierath JR. The role of diet and exercise in the transgenerational epigenetic landscape
28 of T2DM. *Nat Rev Endocrinol*. 2016;12(8):441–51.
29
30 14. Committee on Obstetric Practice. Committee Opinion: Physical Activity and Exercise During
31 Pregnancy and the Postpartum Period. *Am Coll Obstet Gynecol*. 2015;650:1–8.
32
33 15. Evenson KR, Barakat R, Brown WJ, Dargent-Molina P, Haruna M, Mikkelsen EM, et al.
34 Guidelines for Physical Activity during Pregnancy: Comparisons From Around the World. *Am J*
35 *Lifestyle Med*. 2014;8(2):102–21.
36
37 16. Perales M, Artal R LA. Exercise During Pregnancy. *JAMA*. 2017;317(11):1113–4.
38
39 17. Moyer C, Reoyo OR, May L. The Influence of Prenatal Exercise on Offspring Health: A
40 Review. 2016;9:37–42.
41
42 18. U.S. Department of Health and Human Services. 2018 Physical Activity Guidelines Advisory
43 Committee Scientific Report To the Secretary of Health and Human. 2018 Phys Act Guidel
44 Advis Comm Sci Report To Secr Heal Hum Serv [Internet]. 2018; Available from:
45 [https://health.gov/paguidelines/second-](https://health.gov/paguidelines/second-edition/report/pdf/PAG_Advisory_Committee_Report.pdf)
46 [edition/report/pdf/PAG_Advisory_Committee_Report.pdf](https://health.gov/paguidelines/second-edition/report/pdf/PAG_Advisory_Committee_Report.pdf)
47
48 19. Mottola MF, Davenport MH, Ruchat SM, Davies GA, Poitras VJ, Gray CE, et al. 2019 Canadian
49 guideline for physical activity throughout pregnancy. *Br J Sports Med*. 2018;52(21):1339–46.
50
51 20. Ruiz JR, Perales M, Pelaez M, Lopez C, Lucia A, Barakat R. Supervised exercise-based
52 intervention to prevent excessive gestational weight gain: A randomized controlled trial. *Mayo*
53 *Clin Proc*. 2013;88(12):1388–97.
54
55 21. Leung Hui A, Back L, Ludwig S, Gardiner P, Sevenhuysen G, Dean HJ, et al. Effects of lifestyle
56 intervention on dietary intake, physical activity level, and gestational weight gain in pregnant

- women with different pre-pregnancy Body Mass Index in a randomized control trial. *BMC Pregnancy Childbirth*. 2014;14(331):1–9.
22. Wiebe HW, Boulé NG, Chari R, Davenport MH. The Effect of Supervised Prenatal Exercise on Fetal Growth. *Obstet Gynecol*. 2015;125(5):1185–94.
23. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2015;3(10):767–77.
24. Harrison CL, Lombard CB, Strauss BJ, Teede HJ. Optimizing healthy gestational weight gain in women at high risk of gestational diabetes: A randomized controlled trial. *Obesity*. 2013;21(5):904–9.
25. Vinter CA, Jensen DM, Ovesen P, Beck-nielsen H, Jørgensen JS. The LiP (Lifestyle in Pregnancy) Study. *Diabetes Care*. 2011;34:2502–7.
26. Renault KM, Nørgaard K, Nilas L, Carlsen EM, Cortes D, Pryds O, et al. The Treatment of Obese Pregnant Women (TOP) study: A randomized controlled trial of the effect of physical activity intervention assessed by pedometer with or without dietary intervention in obese pregnant women. *Am J Obstet Gynecol*. 2014;210:134.e1-9.
27. Russo LM, Nobles C, Ertel KA, Chasan-Taber L, Whitcomb BW. Physical Activity Interventions in Pregnancy and Risk of Gestational Diabetes Mellitus A Systematic Review and Meta-analysis. *Obstet Gynecol*. 2015;125(3):576–82.
28. Wang C, Wei Y, Zhang X, Zhang Y, Xu Q, Sun Y, et al. A randomized clinical trial of exercise during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women. *Am J Obstet Gynecol*. 2017;1–30.
29. Di Mascio D, Magro-Malosso ER, Saccone G, Marhefka GD, Berghella V. Exercise during pregnancy in normal-weight women and risk of preterm birth: a systematic review and meta-analysis of randomized controlled trials. *American Journal of Obstetrics and Gynecology*. 2016. p. 561–71.
30. Sanabria-Martinez G, Garcia-Hermoso A, Poyatos-Leon R, Alvarez-Bueno C, Sanchez-Lopez M, Martinez-Vizcaino V. Effectiveness of physical activity interventions on preventing gestational diabetes mellitus and excessive maternal weight gain: A meta-analysis. *BJOG An Int J Obstet Gynaecol*. 2015;122(9):1167–74.
31. Koivusalo SB, Rönö K, Klemetti MM, Roine RP, Lindström J, Erkkola M, et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. *Diabetes Care*. 2016;39(1):24–30.
32. Barakat R, Perales M, Cordero Y, Bacchi M, Mottola MF. Influence of Land or Water Exercise in Pregnancy on Outcomes: A Cross-sectional Study. *Med Sci Sports Exerc*. 2017;49(7):1397–403.
33. Backhausen MG, Tabor A, Albert H, Rosthøj S, Damm P, Hegaard HK. The effects of an unsupervised water exercise program on low back pain and sick leave among healthy pregnant women - A randomised controlled trial. *PLoS One*. 2017;12(9):e0182114.

- 1
- 2
- 3
- 4 34. Barakat R, Pelaez M, Lopez C, Montejo R, Coteron J. Exercise during pregnancy reduces the
- 5 rate of cesarean and instrumental deliveries: results of a randomized controlled trial. *J Matern*
- 6 *Neonatal Med.* 2012;25(11):2372–6.
- 7
- 8 35. Nielsen EN, Andersen PK, Hegaard HK, Juhl M. Mode of Delivery according to Leisure Time
- 9 Physical Activity before and during Pregnancy: A Multicenter Cohort Study of Low-Risk
- 10 Women. *J Pregnancy.* 2017;2017:1–8.
- 11
- 12 36. Dumith SC, Domingues MR, Mendoza-Sassi R a, Cesar J a. Physical activity during pregnancy
- 13 and its association with maternal and child health indicators. *Rev Saude Publica.*
- 14 2012;46(2):327–33.
- 15
- 16 37. Owe KM, Nystad W, Stigum H, Vangen S, Bø K. Exercise during pregnancy and risk of
- 17 cesarean delivery in nulliparous women: a large population-based cohort study *Katrine.*
- 18 2016;0(December 2016):1–6.
- 19
- 20 38. Ferrari N, Bae-Gartz I, Bauer C, Janoschek R, Koxholt I, Mahabir E, et al. Exercise during
- 21 pregnancy and its impact on mothers and offspring in humans and mice. *J Dev Orig Health Dis.*
- 22 2017;1–14.
- 23
- 24 39. Huang L, Fan L, Ding P, He Y-H, Xie C, Niu Z, et al. Maternal exercise during pregnancy
- 25 reduces the risk of preterm birth through the mediating role of placenta. *J Matern Neonatal Med.*
- 26 2017;7058(September):1–21.
- 27
- 28 40. Magro-Malosso ER, Saccone G, Di Mascio D, Marhefka GD, Berghella V. Exercise during
- 29 pregnancy risk of preterm birth in overweight and obese women: A systematic review and meta-
- 30 analysis of randomized controlled trials. *Acta Obstet Gynecol Scand.* 2017;215(5):561–71.
- 31
- 32 41. Pomeroy J, Renström F, Gradmark AM, Mogren I, Persson M, Bluck L, et al. Maternal physical
- 33 activity and insulin action in pregnancy and their relationships with infant body composition.
- 34 *Diabetes Care.* 2013;36(2):267–9.
- 35
- 36 42. Harrod CS, Chasan-Taber L, Reynolds RM, Fingerlin TE, Glueck DH, Brinton JT, et al.
- 37 Physical Activity in Pregnancy and Neonatal Body Composition: The Healthy Start Study. *Obs*
- 38 *Gynecol.* 2014;124(1):257–64.
- 39
- 40 43. Clapp JF. Influence of Endurance Exercise and Diet on Human Placental Development and Fetal
- 41 Growth. *Placenta.* 2006;27(6–7):527–34.
- 42
- 43 44. Jackson MR, Gott P, Lye SJ, Ritchie JW, Clapp JF. The effects of maternal aerobic exercise on
- 44 human placental development: placental volumetric composition and surface areas. *Placenta.*
- 45 1995;16(2):179–91.
- 46
- 47 45. The Danish Health Authorities. Recommendations for pregnant women [Internet]. 2014.
- 48 Available from: [https://www.sst.dk/en/health-and-lifestyle/physical-](https://www.sst.dk/en/health-and-lifestyle/physical-activity/recommendations/pregnant-women)
- 49 [activity/recommendations/pregnant-women](https://www.sst.dk/en/health-and-lifestyle/physical-activity/recommendations/pregnant-women)
- 50
- 51 46. Broberg L, Ersbøll AS, Backhausen MG, Damm P, Tabor A, Hegaard HK. Compliance with
- 52 national recommendations for exercise during early pregnancy in a Danish cohort. *BMC*
- 53 *Pregnancy Childbirth.* 2015;15:317.
- 54
- 55 47. Weir Z, Bush J, SC R, McParlin C, Rankin J, Bell R. Physical activity in pregnancy: a

- 1
2
3
4 qualitative study of the beliefs of overweight and obese pregnant women. *BMC Pregnancy*
5 *Childbirth*. 2010;10(18):1–7.
6
- 7 48. Bauer C, Graf C, Platschek AM, Strüder HK, Ferrari N. Reasons, Motivational Factors and
8 Perceived Personal Barriers to Engagement in Physical Activity During Pregnancy Vary Within
9 the BMI Classes - The Prenatal Prevention Project Germany. *J Phys Act Heal*. 2017;32:1–44.
10
- 11 49. Lindqvist M, Persson M, Mogren I. “Longing for individual recognition” – Pregnant women’s
12 experiences of midwives’ counselling on physical activity during pregnancy. *Sex Reprod*
13 *Healthc*. 2018;15:46–53.
14
- 15 50. Hawkins M, Chasan-Taber L, Marcus B, Stanek E, Braun B, Ciccolo J, et al. Impact of an
16 exercise intervention on physical activity during pregnancy: The behaviors affecting baby and
17 you study. *Am J Public Health*. 2014;104(10):e74–81.
18
- 19 51. Oostdam N, Van Poppel MNM, Wouters MG AJ, Eekhoff EMW, Bekedam DJ, Kuchenbecker
20 WKH, et al. No effect of the FitFor2 exercise programme on blood glucose, insulin sensitivity,
21 and birthweight in pregnant women who were overweight and at risk for gestational diabetes:
22 Results of a randomised controlled trial. *BJOG An Int J Obstet Gynaecol*. 2012;119:1098–107.
23
- 24 52. Seneviratne S, Jiang Y, Derraik J, Mccowan L, Parry G, Biggs J, et al. Effects of antenatal
25 exercise in overweight and obese pregnant women on maternal and perinatal outcomes: a
26 randomised controlled trial. *BJOG*. 2016;123:588–97.
27
- 28 53. Ussher M, Lewis S, Aveyard P, Manyonda I, West R, Lewis B, et al. Physical activity for
29 smoking cessation in pregnancy: randomised controlled trial. *BMJ*. 2015;350(h2145):1–10.
30
- 31 54. Gaston A, Prapavessis H. Using a combined protection motivation theory and health action
32 process approach intervention to promote exercise during pregnancy. *J Behav Med*.
33 2014;37(2):173–84.
34
- 35 55. Vinter CA, Jensen DM, Ovesen P, Beck-Nielsen H, Jørgensen JS. The LiP (Lifestyle in
36 Pregnancy) study: A randomized controlled trial of lifestyle intervention in 360 obese pregnant
37 women. *Diabetes Care*. 2011;34:2502–7.
38
- 39 56. Kong KL, Campbell CG, Foster RC, Peterson AD, Lanningham-Foster L. A pilot walking
40 program promotes moderate-intensity physical activity during pregnancy. *Med Sci Sports Exerc*.
41 2014;462–71.
42
- 43 57. Smith KM. The Blossom Project Online: Use of a behaviorally-based website to promote
44 physical activity and prevent excessive gestational weight gain in previously sedentary pregnant
45 women. ProQuest Dissertations and Theses. 2014.
46
- 47 58. Cavalcante SR, Cecatti JG, Pereira RI, Baciuk EP, Bernardo AL, Silveira C. Water aerobics II:
48 maternal body composition and perinatal outcomes after a program for low risk pregnant
49 women. *Reprod Health*. 2009;6(1):1–7.
50
- 51 59. Haakstad L, Bo K. Exercise in pregnant women and birth weight: a randomized controlled trial.
52 *BMC Pregnancy Childbirth*. 2011;11(1):1–7.
53
- 54 60. Tomic V, Sporis G, Tomic J, Milanovic Z, Zigmundovac-Klaic D, Pantelic S. The effect of
55 maternal exercise during pregnancy on abdominal fetal growth. *Croat Med J*. 2013;54:362–8.
56

- 1
- 2
- 3
- 4 61. De Oliveria Melo AS, Silva JLP, Tavares JS, Barros VO, Leite DFB, Amorim MMR. Effect of a
- 5 physical exercise program during pregnancy on uteroplacental and fetal blood flow and fetal
- 6 growth: A randomized controlled trial. *Obstet Gynecol*. 2012;120(2 PART 1):302–10.
- 7
- 8 62. Currie S, Sinclair M, Murphy MH, Madden E, Dunwoody L, Liddle D. Reducing the Decline in
- 9 Physical Activity during Pregnancy: A Systematic Review of Behaviour Change Interventions.
- 10 *PLoS One*. 2013;8(6):1–12.
- 11
- 12 63. Pearce E, Evenson K. Strategies to promote physical activity during pregnancy. *Am J Lifestyle*
- 13 *Med*. 2013;7(1):1–19.
- 14
- 15 64. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of
- 16 interventions: Template for intervention description and replication (TIDieR) checklist and
- 17 guide. *BMJ*. 2014;348(March):1–13.
- 18
- 19 65. Borg GAV. Psychophysical bases of perceived exertion. 1982.
- 20
- 21 66. Bennett G. Miller, W. R. and Rollnick, S. (1991) Motivational interviewing: Preparing people to
- 22 change addictive behavior. New York: Guilford Press, 1991. Pp. xvii + 348. £24.95 hardback,
- 23 £11.50 paper. ISBN 0–89862–566–1. *J Community Appl Soc Psychol* [Internet]. 1992 Nov 1
- 24 [cited 2020 Aug 3];2(4):299–300. Available from:
- 25 <http://doi.wiley.com/10.1002/casp.2450020410>
- 26
- 27 67. Markland D, Ryan RM, Tobin VJ, Rollnick S. Motivational Interviewing and Self–
- 28 Determination Theory. *J Soc Clin Psychol*. 2005;24(6):811–31.
- 29
- 30 68. Michie S, Ashford S, Sniehotta FF, Dombrowski SU, Bishop A, French DP. A refined taxonomy
- 31 of behaviour change techniques to help people change their physical activity and healthy eating
- 32 behaviours: The CALO-RE taxonomy. *Psychol Heal*. 2011;26(11):1479–98.
- 33
- 34 69. De Vries HJ, Kooiman TJM, van Ittersum MW, van Brussel M, de Groot M. Do activity
- 35 monitors increase physical activity in adults with overweight or obesity? A systematic review
- 36 and meta-analysis. *Obesity*. 2016;24(10):2078–91.
- 37
- 38 70. Cadmus-bertram LA, Marcus BH, Patterson RE, Parker BA, Morey BL. Randomized Trial of a
- 39 Fitbit-Based Physical Activity Intervention for Women. *Am J Prev Med*. 2015;49(3):414–8.
- 40
- 41 71. Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G, Freedson PS.
- 42 Development and validation of a pregnancy physical activity questionnaire. *Med Sci Sports*
- 43 *Exerc*. 2004;36(10):1750–60.
- 44
- 45 72. Santini De Oliveira C, Dos Santos Imakawa T, Christine Dantas Moises E. Physical Activity
- 46 during Pregnancy: Recommendations and Assessment Tools. *Rev Bras Ginecol Obs*.
- 47 2017;39:424–32.
- 48
- 49 73. Schuster S, Sklempe Kokic I, Sindik J. Measuring Physical Activity in Pregnancy Using
- 50 Questionnaires: a Meta-Analysis. *Acta Clin Croat*. 2016;55(3):440–51.
- 51
- 52 74. Abeysekera M V, Morris JA, O ’sullivan AJ. Techniques to measure free-living energy
- 53 expenditure during pregnancy – A guide for clinicians and researchers. *Obstet Med*.
- 54 2014;7(2):60–5.
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 75. Van Hees VT, Renström F, Wright A, Gradmark A, Catt M, Chen KY, et al. Estimation of daily
- 5 energy expenditure in pregnant and Non-Pregnant women using a Wrist-Worn Tri-Axial
- 6 accelerometer. *PLoS One*. 2011;6(7):1–10.
- 7
- 8 76. Lof M, Forsum E. Activity pattern and energy expenditure due to physical activity before and
- 9 during pregnancy in healthy Swedish women. *Br J Nutr*. 2006;95(2):296–302.
- 10
- 11 77. Wong WW, Roberts SB, Racette SB, Das SK, Redman LM, Rochon J, et al. The Doubly
- 12 Labeled Water Method Produces Highly Reproducible Longitudinal Results in. *J Nutr*.
- 13 2014;144:777–83.
- 14
- 15 78. RAND Corporation. 36-Item Short Form Survey Instrument (SF-36). 2016;5–10.
- 16
- 17 79. Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. SF-36v2
- 18 Health Survey. 2004;
- 19
- 20 80. Jomeen J, Martin CR. The factor structure of the SF-36 in early pregnancy. *J Psychosom Res*.
- 21 2005 Sep;59(3):131–8.
- 22
- 23 81. Bland HW, Melton BF, Marshall ES, Nagle JA. Measuring Exercise Self-Efficacy in Pregnant
- 24 Women: Psychometric Properties of the Pregnancy-Exercise Self-Efficacy Scale (P-ESES). *J*
- 25 *Nurs Meas*. 2013 Dec 1;21(3):349–59.
- 26
- 27 82. Bendix EJ, Holmberg Krøner F, De Place Knudsen S, Bendix JM, Molsted S. Cross-cultural
- 28 adaption, translation and reliability tests of the Danish version of the Pregnancy Exercise Self-
- 29 Efficacy Scale. *Sex Reprod Healthc* [Internet]. 2020 Dec 1 [cited 2020 Aug
- 30 11];26(May):100542. Available from: <https://doi.org/10.1016/j.srhc.2020.100542>
- 31
- 32 83. Mullan E, Markland D, Ingledew DK. A graded conceptualisation of self-determination in the
- 33 regulation of exercise behaviour: Development of a measure using confirmatory factor analytic
- 34 procedures. Vol. 23, ~) Pergamon Person. individ. Diff. 1997.
- 35
- 36 84. Mullan E, Markland D, Mullan E. Variations in Self-Determination Across the Stages of Change
- 37 for Exercise in Adults. Vol. 21, Motivation and Emotion. Markland & Hardy; 1997.
- 38
- 39 85. Markland D, Tobin V. A Modification to the Behavioural Regulation in Exercise Questionnaire
- 40 to Include an Assessment of Amotivation. *J Sport Exerc Psychol*. 2004 Jun;26(2):191–6.
- 41
- 42 86. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality
- 43 Index : A New Instrument *Psychiatric Practice and Research*. *Psychiatry Res*. 1989;28:193–213.
- 44
- 45 87. University of Pittsburgh. Pittsburgh Sleep Quality Index (PSQI). 1988;(3):6.
- 46
- 47 88. Qiu C, Gelaye B, Zhong Q-Y, Enquobahrie DA, Frederick IO, Williams MA. Construct validity
- 48 and factor structure of the Pittsburgh Sleep Quality Index among pregnant women in a Pacific-
- 49 Northwest cohort. *Sleep Breath*. 2016;20(1):293–301.
- 50
- 51 89. Cox JL (John L, Holden J. Perinatal mental health : a guide to the Edinburgh Postnatal
- 52 Depression Scale (EPDS). Gaskell; 2003. 125 p.
- 53
- 54 90. Zierau F, Bille A, Rutz W, Bech P. The Gotland Male Depression Scale: A validity study in
- 55 patients with alcohol use disorder. *Nord J Psychiatry* [Internet]. 2002 Jan 12 [cited 2019 Apr
- 56 11];56(4):265–71. Available from:
- 57
- 58
- 59
- 60

- 1
2
3
4 <http://www.tandfonline.com/doi/full/10.1080/08039480260242750>
5
- 6 91. Magovcevic M, Addis ME. The Masculine Depression Scale: Development and psychometric
7 evaluation. *Psychol Men Masc* [Internet]. 2008 Jul [cited 2019 Apr 11];9(3):117–32. Available
8 from: <http://doi.apa.org/getdoi.cfm?doi=10.1037/1524-9220.9.3.117>
9
- 10 92. Madsen SA. Spædbarnet i faderens verden (Infants' within the world of the father). *Psyke &*
11 *Logos* [Internet]. 2008;29(2):669–87. Available from:
12 <https://tidsskrift.dk/psyke/article/view/8503>
13
- 14 93. Craig P. Developing and evaluating complex interventions.
- 15 94. Moore G, Audrey S, Barker M, Bond L, Bonell C, Cooper C, et al. Process evaluation in
16 complex public health intervention studies: the need for guidance. *J Epidemiol Community*
17 *Health*. 2014 Feb;68(2):101–2.
- 18 95. Hoffmann TC, Eructi C, Glasziou PP. Poor description of non-pharmacological interventions:
19 analysis of consecutive sample of randomised trials. *BMJ*. 2013 Sep;347:f3755.
- 20 96. Moore G, Raisanen L, Moore L, Ud Din N, Murphy S. Mixed-method process evaluation of
21 the Welsh National Exercise Referral Scheme. *Health Educ*. 2013 Oct;113(6):476–501.
- 22 97. Glasgow RE, Vogt TM, Boles SM. Evaluating the Public Health Impact of Health Promotion
23 Interventions: The RE-AIM Framework. 1999 [cited 2018 Mar 8];89(9). Available from:
24 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508772/pdf/amjph00009-0018.pdf>
- 25 98. R Core Team (2020). R: A language and environment for statistical computing. R Foundation
26 for Statistical Computing, Vienna, Austria. [Internet]. Available from: <https://www.r-project.org/>
- 27 99. UK Chief Medical Officers. UK Chief Medical Officers Recommendations 2017: Physical
28 Activity in Pregnancy. 2017.
- 29 100. UK Chief Medical Officers. UK Chief Medical Officers Recommendations 2017: Physical
30 Activity in Pregnancy, guidance. 2017;1–7.
- 31 101. Verdiere S, Guinhouya BC, Salerno D, Deruelle P. Should physical activity be contraindicated
32 during pregnancy in relation to its potentially related risks? 2017;45:104–11.
- 33 102. Melo ASDO, Silva JLP, Tavares JS, Barros VO, Leite DFB, Amorim MMR. Effect of a Physical
34 Exercise Program During Pregnancy on Uteroplacental and Fetal Blood Flow and Fetal Growth.
35 2012;120(2):302–10.
- 36 103. Rêgo AS, Alves MTSS de B e, Batista RFL, Ribeiro CCC, Bettiol H, Cardoso VC, et al.
37 Physical activity in pregnancy and adverse birth outcomes. *Cad Saude Publica*. 2016;32(11):1–
38 10.
- 39 104. Charlesworth S, Foulds HJ a, Burr J, Bredin SSD. Evidence-based risk assessment and
40 recommendations for physical activity clearance: pregnancy. *Appl Physiol Nutr Metab*.
41 2011;36(S1):S154–89.
- 42 105. Brickwood K, Hons B, Watson G, Brien JO, Williams AD. Consumer-Based Wearable Activity
43 Trackers Increase Physical Activity Participation : Systematic Review and Meta-Analysis
44 Corresponding Author : 2019;7(4).
- 45
46
47
48
49
50
51
52
53
54
55

- 1
2
3
4 106. Wright SP, Hall Brown TS, Collier SR, Sandberg K. How consumer physical activity monitors
5 could transform human physiology research. *Am J Physiol - Regul Integr Comp Physiol*.
6 2017;312:R358–67.
7
- 8 107. Guérin E, Ferraro ZM, Adamo KB, Prud'homme D. The Need to Objectively Measure Physical
9 Activity During Pregnancy: Considerations for Clinical Research and Public Health Impact.
10 *Matern Child Health J* [Internet]. 2018;22(5):637–41. Available from:
11 <http://dx.doi.org/10.1007/s10995-018-2475-4>
12
- 13 108. Grym K, Niela-vilén H, Ekholm E, Hamari L, Azimi I, Rahmani A, et al. Feasibility of smart
14 wristbands for continuous monitoring during pregnancy and one month after birth. 2019;9:1–9.
15
- 16 109. Wear and Care Tips for Garmin Watches [Internet]. [cited 2019 Sep 8]. Available from:
17 [https://support.garmin.com/en-](https://support.garmin.com/en-US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn)
18 [US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn](https://support.garmin.com/en-US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn)
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Procedures and measurements in the FitMum study


| Visit number | Visit 1 Screening and baseline testing | E-mail Randomization | Visit 2 | Visit 3 | Visit 4 Delivery | Visit 5 | |
|--|---|-----------------------------|--------------------|--------------------|--------------------------|-----------------------------------|--|
| Gestational age (week+days) | Max. 15+0 | One week after inclusion | Week 28+0- 6 | Week 34+0- 6 | Approximately week 40 | 7-14 days after delivery | One year after delivery |
| Ultrasound scan | x | | | | | | |
| Verbal information about study | x | | | | | | |
| Medical interview to assess in- and exclusion criteria | x | | | | | | |
| Demographic and anthropometric data | x | | | | | | |
| Medical history, concomitant disease, and previous medication | x | | | | | | |
| Medical history, PA level, demographic and anthropometric data of the participant's partner | x | | | | | | |
| Written informed consent | x | | | | | | |
| Activity tracker and associated oral and written information | x | | | | | | |
| Randomization | | x | | | | | |
| METHODOLOGY FOR OBTAINING ENDPOINTS | | | | | | | |
| Activity tracker | Continuously during the trial and one year after delivery | | | | | | |
| Maternal body weight | x | | x | x | x | x | Six times at home during postpartum |

| | | | | | | | |
|---|---|-----------|---|---|---|---|------------------------------|
| Doubly labelled water | | | x | | | | |
| Questionnaires: PPAQ-DK, SF-36, PSQI, P-ESES, BREQ-2, sickness absence + pelvic and low back pain | x | | x | x | | | x |
| Maternal blood samples | x | | x | x | x | | |
| Paternal blood sample | | | | | x | | |
| Umbilical cord blood sample | | | | | x | | |
| Placenta samples | | | | | x | | |
| DXA-scan | | | | | | x | |
| Breast milk sample | | | | | | x | |
| Qualitative interview | x | | | x | | | x |
| Observation and autodocumentation | | Recurring | | | | | |
| ASQ-3 | | | | | | | x |
| Growth assessment at general practitioner | | | | | | | 5 weeks, and 5 and 12 months |
| Parental mental well-being questionnaire | | | | | | | 6-8 weeks postpartum |
| Seven-day child accelerometer | | | | | | | x |
| SAFETY | | | | | | | |
| Record adverse events | | | x | x | | | |
| Symphysis-fundal height | | | x | x | | | |

ASQ-3: Ages and Stages Questionnaire 3, BREQ-2: Behavioural Regulations Exercise Questionnaire, DXA: Dual-energy X-ray absorptiometry, P-ESES: Pregnancy Exercise Self-efficacy Scale, PPAQ-DK: Pregnancy PA Questionnaire (Danish version), PSQI: Pittsburgh Sleep Quality Index, SF-36: The Medical Outcomes Study Short Form 36.

Figure legends

Figure 1: Flow diagram of the FitMum randomized controlled trial

Figure 1: Flow diagram of the FitMum randomized controlled trial.

BMJ Open

Structured supervised exercise training or motivational counselling during pregnancy on physical activity level and health of mother and offspring: FitMum Study Protocol

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2020-043671.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 30-Dec-2020 |
| Complete List of Authors: | <p>Roland , Caroline ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Knudsen, Signe ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences</p> <p>Alomairah, Saud; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Saudi Electronic University, Department of Public Health</p> <p>Andersen , Anne ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Bendix , Jane ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics</p> <p>Clausen , Tine ; Nordsjaellands Hospital, Department of Gynaecology and Obstetrics; University of Copenhagen Faculty of Health and Medical Sciences, Department of Clinical Medicine</p> <p>Molsted, Stig; Nordsjaellands Hospital, Department of Clinical Research</p> <p>Jensen, AK; University of Copenhagen, Department of Public Health; Nordsjaellands Hospital, Department of Clinical Research</p> <p>Teilmann , Grete ; Nordsjaellands Hospital, Department of Paediatrics</p> <p>Jespersen , Astrid ; University of Copenhagen Copenhagen Centre for Health Research in the Humanities, The Saxo Institute</p> <p>Larsen, Jakob ; Danmarks Tekniske Universitet, Department of Applied Mathematics and Computer Science</p> <p>Hall , Gerrit ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences; Rigshospitalet, Clinical Metabolomics Core Facility, Clinical Biochemistry</p> <p>Andersen, Emil ; University of Copenhagen Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research</p> <p>Barrès, Romain ; University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research</p> <p>Mortensen , Ole ; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences</p> <p>Maindal, Helle; Aarhus Universitet, Department of Public Health; Steno Diabetes Center Copenhagen</p> <p>Tarnow , Lise ; Nordsjaellands Hospital, Department of Clinical Research; Steno Diabetes Center Copenhagen</p> <p>Løkkegaard, Ellen; Nordsjaellands Hospital, Department of Gynecology and Obstetrics; University of Copenhagen Faculty of Health and Medical</p> |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | |
|--------------------------------------|---|
| | Sciences, Department of Clinical Medicine Stalknecht, Bente; University of Copenhagen Faculty of Health and Medical Sciences, Department of Biomedical Sciences |
| Primary Subject Heading : | Sports and exercise medicine |
| Secondary Subject Heading: | Obstetrics and gynaecology |
| Keywords: | OBSTETRICS, SPORTS MEDICINE, PUBLIC HEALTH, CLINICAL PHYSIOLOGY |
| | |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Structured supervised exercise training or motivational counselling during pregnancy on**
5 **physical activity level and health of mother and offspring: FitMum Study Protocol**
6
7

8 *Caroline Borup Roland ^{a, b}, *Signe de Place Knudsen ^{b, a}, *Saud A Alomairah ^{a, b, c}, Anne Dsane
9 Andersen ^b, Jane Bendix ^b, Tine D. Clausen ^{b, d}, Stig Molsted ^e, Andreas Kryger Jensen ^{f, e}, Grete
10 Teilmann ^g, Astrid Pernille Jespersen ^h, Jakob Eg Larsen ⁱ, Gerrit van Hall ^{a, j}, Emil Andersen ^k,
11 Romain Barrès ^k, Ole Hartvig Mortensen ^a, Helle Terkildsen Maindal ^{l, m}, Lise Tarnow ^{e, n}, Ellen
12 Løkkegaard ^{b, d}, Bente Stallknecht ^a
13
14

15 ^a University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark

16 ^b Nordsjaellands Hospital, Department of Gynaecology and Obstetrics, Hillerod, Denmark

17 ^c Saudi Electronic University, College of Health Sciences, Public Health Department, Riyadh, Saudi
18 Arabia

19 ^d University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark

20 ^e Nordsjaellands Hospital, Department of Clinical Research, Hillerod, Denmark

21 ^f University of Copenhagen, Department of Public Health, Copenhagen, Denmark

22 ^g Nordsjaellands Hospital, Department of Paediatrics, Hillerod, Denmark

23 ^h University of Copenhagen, Copenhagen Centre for Health Research in the Humanities, The Saxo
24 Institute, Copenhagen, Denmark

25 ⁱ Technical University of Denmark, Department of Applied Mathematics and Computer Science,
26 Lyngby, Denmark

27 ^j Rigshospitalet, Clinical Metabolomics Core Facility, Clinical Biochemistry, Copenhagen, Denmark

28 ^k University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research,
29 Copenhagen, Denmark

30 ^l Aarhus University, Department of Public Health, Aarhus, Denmark

31 ^m Steno Diabetes Center Copenhagen, Gentofte, Denmark

32 ⁿ Steno Diabetes Center Sjaelland, Holbaek, Denmark

33
34
35
36
37 * Contributed equally
38
39
40
41

42 **Corresponding author:** Caroline Borup Roland, University of Copenhagen, Department of
43 Biomedical Sciences, Copenhagen, Denmark. E-mail: cba@sund.ku.dk
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

- **Introduction:** A physically active lifestyle during pregnancy improves maternal and offspring health, but can be difficult to follow. In Denmark, less than 40% of pregnant women meet physical activity (PA) recommendations. The FitMum study aims to explore strategies to increase PA during pregnancy among women with low PA and assess the health effects of PA. This paper presents the FitMum protocol, which evaluates the effects of structured supervised exercise training or motivational counselling supported by health technology during pregnancy on PA level and health of mother and offspring.
- **Methods and analysis:** A single-site three-arm randomized controlled trial, which aims to recruit 220 healthy, pregnant women with gestational age (GA) no later than week 15 and whose PA level does not exceed one hour/week. Participants are randomized to one of three groups: structured supervised exercise training consisting of three weekly exercise sessions, motivational counselling supported by health technology, or a control group receiving standard care. The interventions take place from randomization until delivery. The primary outcome is min/week of moderate-to-vigorous-intensity PA as determined by a commercial activity tracker, collected from randomization until GA of 28 weeks and 6 days, and the secondary outcome is gestational weight gain. Additional outcomes are complementary measures of PA; clinical and psychological health parameters in participant, partner, and offspring; analyses of blood, placenta and breast milk samples; process evaluation of interventions; personal understandings of PA.
- **Ethics and dissemination:** The study is approved by the Danish National Committee on Health Research Ethics (# H-18011067) and the Danish Data Protection Agency (# VD-2018-336). Findings will be disseminated via peer-reviewed publications, at conferences, and to health professionals via science theatre performances.
- **Strengths and limitations:**
 - The efficacy of structured supervised exercise training and motivational counselling supported by health technology to improve physical activity and reduce weight gain of pregnant women is directly compared in a randomized controlled trial.
 - The trial involves complex interventions and is held in one site only, so generalizability and fidelity might be a concern. Yet, as one of the additional outcomes, a process evaluation is conducted alongside the trial to explore how the interventions are carried out and adapted.
 - The study is comprehensive and multidisciplinary in its design. Many different methodologies are used, and mother, partner and offspring are studied.
 - Activity trackers can increase physical activity level and are feasible tools in everyday life, but commercial activity trackers have limited validity for the quantification of physical activity.

- Physical activity is extensively measured using three different methods: commercial activity trackers, gold standard doubly labelled water, and the validated Pregnancy Physical Activity Questionnaire.

Trial registration: ClinicalTrials.gov (# NCT03679130). Registered September 20, 2018.

Protocol version: This paper was written per the study protocol version 8 dated August 28, 2019.

For peer review only

Introduction

Although the health effects of physical activity (PA) are widely acknowledged, the means of how to best implement and maintain PA in everyday life are lacking (1). Pregnancy can be regarded as a window of opportunity to implement good habits of PA as pregnant women are in regular contact with health professionals and are likely motivated to adopt healthy behaviours, as illustrated by reduced alcohol consumption and smoking cessation (2–4). On the other hand, pregnancy can be seen as an opportunity to be exempt from fitness demands and bodily ideals, and can be experienced as a troublesome time due to fatigue and discomfort (5,6). Moreover, pregnancy is a relatively short period of time in regards to forming new habits (6), and that may affect the motivations and challenges in being physically active. Furthermore, differences in work status, social relations, and family situations, as well as varying material and structural conditions, may contribute to the implementation of PA (7).

Insufficient PA is a global problem (8) that occurs also during pregnancy (8–12). It is a significant public health issue, as increasing evidence suggests that lifestyle during pregnancy influences health in the mother and her offspring (4,13). Regular PA during pregnancy promotes clinical and metabolic health in both mother and offspring and reduces the number of complications during pregnancy and delivery (14–19). PA reduces gestational weight gain (20–26), the risk of gestational diabetes mellitus (27–32), the intensity of low back pain (33), the risk of caesarean delivery (22,29,34–37) and improves maternal body composition (38). Additionally, a physically active pregnancy improves the health of the offspring by normalizing birth weight (22), reducing the risk of preterm delivery (39,40), and improving neonatal body composition (41,42) as well as placental function (43,44), which results in optimized intrauterine growth conditions.

The Danish Health Authorities recommend that healthy pregnant women are physically active for at least 30 min/day at moderate intensity (45), but only 38% of Danish pregnant women achieve this recommended level (46). Several barriers to PA during pregnancy are addressed in the literature (47), including anxiety about over-doing exercise, low motivation to adopt an active lifestyle during pregnancy, changing energy levels throughout the pregnancy, and lack of time to be physically active (48). The latest recommendations on lifestyle interventions during pregnancy support individualized advice on how to increase the PA level rather than a generic approach (6), as pregnant women prefer personalized information (49). Consequently, policymakers, healthcare professionals, and pregnant women advocate for evidence-based guidance on how to implement PA in everyday life during pregnancy safely and effectively, with approaches that meet the needs, preferences, and choices of the pregnant woman.

During the past decades, many PA intervention studies in pregnant women have been conducted on overweight and obese populations (23,24,26,28,50–57) as well as in healthy normal-weight pregnant women (20,21,32,33,58–61). Still, none of these studies have focused primarily on investigating the effect of the exercise interventions on actual PA level in pregnant women nor have they used novel objective methods to measure actual PA levels. Structured, supervised exercise training and motivational counselling have been applied separately in pregnant women

(20,21,23,24,26,28,32,33,50–55,58–63), but the relative efficacy of these interventions has not been compared; this hampers the evidence-based implementation of effective exercise programs into everyday life.

Objective

This paper describes the protocol of the FitMum study, which is centred around a randomized controlled trial (RCT). The FitMum RCT aims to evaluate the effects of structured supervised exercise training (EXE) and motivational counselling supported by health technology (MOT) compared to standard care (CON) on PA level and body weight gain during pregnancy. Additional aims of the study are to investigate the effects of EXE and MOT on clinical and metabolic health parameters in both mother and offspring. We will also explore how the FitMum exercise programs are carried out and adopted by conducting a process evaluation. In addition, we explore the personal attribution of meaning to the experiences and practices of PA among participants. Furthermore, we investigate how social, structural, and cultural factors facilitate or hinder the successful implementation of exercise during pregnancy.

Methods

Study design

The FitMum RCT is a single-site, three-arm trial study.

Setting

The study is carried out at the Department of Gynaecology and Obstetrics, Nordsjaellands Hospital (NOH), Hillerod, in the Capital Region of Denmark, where approximately 4,000 women give birth per year. NOH is a public hospital and participation in FitMum is free of charge.

Participants

220 healthy, pregnant women are included in this study. Inclusion criteria are an obtained written informed consent, maternal age of 18 years or older, gestational age (GA) of max. 15 weeks, ultrasonic confirmed viable intrauterine pregnancy, body mass index of 18.5-45 kg/m² and body weight <150 kg (pre-pregnancy weight or first measured weight in pregnancy), ability to wear a wrist-worn activity tracker 24/7 until one year postpartum and having a smartphone. Exclusion criteria are structured exercise at moderate-to-vigorous intensity for more than one hour/week during early pregnancy, previous preterm delivery, obstetric or medical complications, multiple pregnancies, inability to speak Danish, or alcohol or drug abuse.

Recruitment and inclusion

Participants are recruited 1) *via* booking confirmation of a first-trimester scan, 2) at face-to-face meetings during the first-trimester scan, and 3) through posters, flyers, and social media. Before inclusion, interested women answer an online, one-page pre-screening questionnaire. Eligible participants and their partners are invited to the first visit at NOH as soon as possible and no later than GA of 14 weeks and 6 days. At visit 1, the woman is verbally informed about the study and screened according to in- and exclusion criteria. Women who have not had a first-trimester scan are vaginally

1
2
3
4 scanned to confirm a singleton, viable intrauterine pregnancy. All eligible women are included and
5 written informed consent is obtained (supplemental file 1). Written informed consent is also obtained
6 from the biological father or other holders of custody as biological samples are collected from the
7 offspring and, if known, from the biological father (supplemental file 2). A short semi-structured
8 interview with the participant is recorded. The interview provides knowledge of the participant's
9 thoughts on participating in a research project, knowledge of prior and current PA level, and
10 experiences with health technologies. After inclusion, anthropometric and demographic information
11 and a blood sample are collected.
12
13
14

15 At the end of visit 1, the participant receives a commercial activity tracker, Garmin Vivosport. The
16 participant is instructed to wear the tracker continuously 24/7 from the one-week baseline period until
17 one year postpartum, except during charging. The activity tracker is water-resistant and determines the
18 frequency, duration, and intensity of activity periods on a minute-to-minute basis. The data from the
19 activity tracker are wirelessly synced to the associated app, Garmin Connect, provided by Garmin
20 International, and the research platform Fitabase (Small Steps Labs LLC), through which the compliance
21 of wearing and synchronizing the data from the tracker are continuously monitored during the study.
22
23
24

25 **Baseline period and randomization**

26 After inclusion, the baseline PA level of the participant is measured by the activity tracker for one
27 week. After the baseline period, participants are randomized into the CON, EXE, or MOT groups
28 (Figure 1). The target number of participants randomized to each group is 44, 88, and 88, respectively,
29 in order to have more participants in the intervention groups. Randomization is performed via a
30 numbered randomization list administered through the database Research Electronic Data Capture
31 (REDCap), and the investigators are blinded to the procedure. Blinding of participants is considered
32 impossible due to the inherent content of the exercise interventions. The participant is informed about
33 the assigned group by email, and participants in EXE and MOT receive written information containing
34 guidelines from the Danish Health Authorities about PA during pregnancy.
35
36
37
38

39 **Patient and public involvement**

40 Template for Intervention Description and Replication (64) was used as inspiration for the development
41 and description of the study. As a part of the development phase, stakeholders in the field were
42 involved in discussions and sharing of knowledge. Additionally, 27 semi-structured interviews with
43 Danish pregnant women, midwives, and obstetricians were performed to explore the feasibility of such
44 a study as well as the motivational factors and barriers to PA during pregnancy. Participants are not
45 directly involved in the recruitment and conduct of the study, but a process evaluation is conducted and
46 personal understandings of the participants are obtained via interviews (see below). The insights from
47 the study will be shared with the participants at an information meeting after the end of the study.
48
49
50
51
52
53
54
55
56
57
58
59
60

Interventions

Standard care at the hospital

All three groups are offered the standard care that applies to women giving birth at NOH. This consists of three appointments with their general practitioner (GA week 6-10, 25 and 32), five to six midwife consultations (GA week 14-17, 29, 36, 38, 40 and if still pregnant around week 41 as well) and ultrasonic scans at GA week 12 and 20.

Standard care control group (CON)

Participants in CON wear an activity tracker to determine their activity level. The face of the tracker looks like a normal watch showing only time and battery life.

Structured supervised exercise training intervention (EXE)

The targeted PA level for all participants in EXE and MOT is at least 30 min/day at a moderate intensity as recommended to healthy pregnant women (6) and all participants are informed hereof if randomized to EXE or MOT. In EXE, exercise training takes place in teams and is supervised by health professionals (exercise physiologists, physiotherapists, public health scientists). It consists of three weekly one-hour exercise sessions at moderate intensity, including two exercise sessions in a gym and one in a public swimming pool. The gym sessions consist of a combination of aerobic and resistance training with 30 min stationary bike training (a combination of hill climbing and high cadence intervals) and 30 min of other exercise, e.g. elastic bands, exercise balls, mats, dumbbells or body weight. In the swimming pool, participants do 15 min of swimming and 45 min of water exercises with plates, balls, dumbbells or body weight. Moderate intensity during training sessions is assessed using both heart rate monitoring of 65-80% of age-predicted maximal heart rate (from the activity tracker) and perceived exertion in the range of 12-14 on Borg's conventional 6-20-point scale (64), as recommended by the American College of Obstetricians and Gynaecologists (14). If a participant experiences any pain or needs to slow down, the content of exercise sessions (repetitions and/or resistance) is individually adjusted accordingly. Special attention is paid to the newly recruited participants. Exercise sessions are offered at seven different times per week, and participants are recommended to sign up for three of these sessions. The sessions are held early mornings or late afternoons all weekdays, and before noon on Fridays and Saturdays.

Motivational counselling supported by health technology (MOT)

This intervention is comprised of four individual and three group counselling sessions as well as weekly SMS-reminders. The overall focus of both the individual and group counselling sessions is based on what already motivates the participants to increase or maintain their PA level. The motivation technique applied is inspired by motivational interviewing (65), self-determination theory (66), and behaviour change techniques (67).

All four *individual sessions* last one hour and are led by professional health counsellors (exercise physiologists, physiotherapists, public health scientists). The sessions aim to discuss the participant's

1
2
3
4 barriers, wishes, needs, knowledge, and former PA experiences to identify individual characteristics
5 and motivation towards a more physically active lifestyle. Aside from measuring the PA level, the
6 activity trackers are also used as an intervention element to motivate the participants to increase their
7 PA levels (68). During individual sessions, feedback on recent PA performances is provided based on
8 activity data acquired from the activity tracker, in order to give the participants insight into their PA
9 level. The participants will, with guidance from the counsellor, set their own activity goals and make an
10 individual action plan to increase the PA level, which may have a motivating effect on PA behaviour
11 (68,69). Individual sessions are scheduled during the daytime as conveniently for the participant as
12 possible.
13
14
15

16
17 The first *group session* lasts one hour and aims to inform the participants about guidelines for PA,
18 benefits associated with PA during pregnancy, and possible ways to increase PA during pregnancy. In
19 the following two two-hour group sessions, the interaction between the participants is used to create
20 meaningful group processes such as support, experience exchange, reflection, learning, and
21 development. These sessions focus on the discussion of relevant topics concerning PA during
22 pregnancy, and the counsellor acts as a facilitator through the session, with the topics of conversation
23 chosen by the participants. Issues like postpartum PA, the pelvic floor, uterine contractions, diastasis
24 recti, and myths about pregnancy PA are discussed. Group sessions are held late afternoons, or before
25 noon for those on maternity leave.
26
27
28

29 The weekly SMS-reminders have supportive and motivating content and are used to encourage the
30 participants to achieve a moderate PA level. The texts are chosen based on every participant's PA level
31 during the last week measured by the activity tracker. One example of the text: "You have been
32 exercising regularly for an extended period of time. Well done. Good habits make it easier for you to
33 continue as your belly gets bigger and heavier."
34
35

36 **Outcome measures**

37 The data collection procedures are illustrated in Table 1.
38

39 **Primary outcome: physical activity level**

40
41 The primary outcome of FitMum RCT is min/week of moderate-to-vigorous-intensity PA measured
42 continuously from randomization to GA of 28 weeks and 6 days as determined by a wrist-worn activity
43 tracker, Garmin Vivosport, with a built-in heart rate monitor and accelerometer.
44
45

46 **Secondary outcome: gestational weight gain**

47 Body weight of the participant before pregnancy is self-reported. The body weight during pregnancy is
48 measured five times from inclusion until delivery on the same scale (Seca 799) with the participant in
49 light clothes and without shoes.
50
51
52
53
54
55
56

Additional outcomes

Complementary measures of physical activity

Complementary measures of PA are obtained by the Danish version of ‘Pregnancy Physical Activity Questionnaire’ (PPAQ) (70) named PPAQ-DK, and by the doubly labelled water technique (71). PPAQ is a semi-quantitative and subjective instrument, which has been validated (70) and is considered one of the most valid and reliable questionnaires for the assessment of PA level in pregnant women (72). Our research group has translated PPAQ to Danish and validated it in a Danish pregnant population (73).

The doubly labelled water technique is the ‘gold standard’ technique to measure free-living energy expenditure objectively, and is safe, even for pregnant women, as it relies on stable, non-radioactive isotopes (74–77). The participants are administered a glass of water for oral intake containing 0.1 g of 99.98 % $^2\text{H}_2\text{O}$ and 1.6 g of 10% ^{18}O per kg body weight. In total, five post-dose urine samples are collected in the morning (not the first urine void of the day); on the day after oral water dosage, and after four, seven, 11, and 14 days. The urine samples are stored in the participant’s freezer and later at $-80\text{ }^\circ\text{C}$.

In addition, the PA of the participants is determined from GA week 29 until delivery and in the first year postpartum by the activity tracker. The measures of PA include active calories, active time, steps, heart rate, moderate- and vigorous-intensity activity, floors climbed, MET-min/week, and type of activity, which is recognized automatically by the tracker.

Clinical and psychological health parameters in participant, partner, and offspring

A variety of clinical and psychological health parameters are obtained from the participant, her partner, and her offspring. *Clinical data* regarding pregnancy, delivery, and neonatal outcomes are collected from medical records. *Health-related quality of life* is determined in the participant by the Danish version of the Medical Outcomes Study Short Form 36 (SF-36) (78,79), which has also been validated in pregnant women (80). *Exercise self-efficacy* is determined by the Danish version of the Pregnancy Exercise Self-Efficacy Scale (P-ESES) (81). P-ESES has been translated into Danish and validated in a Danish pregnant population by our research group (82). *PA motivation* is determined by the Danish version of the Behavioural Regulation in Exercise Questionnaire (BREQ-2) (83–85), which is the most widely used measure of the continuum of behavioural regulation in exercise psychology research. *Sleep quantity and quality* are assessed in the participant by the activity tracker and by the Danish version of the self-administered questionnaire Pittsburgh Sleep Quality Index (PSQI) (86,87). The PSQI is considered a valid and reliable tool to assess sleep metrics among pregnant women (88). In addition, a validation of activity trackers to measure sleep will be conducted using polysomnography in a subgroup of women already participating in the FitMum study. *Sick leave and pelvic and low back pain* are registered by asking the participant whether she has been absent from work/study and on sick leave during her pregnancy and whether she has experienced pelvic and/or low back pain before and during her pregnancy. *Maternal body composition* is determined from total body water measured by doubly labelled water technique and by a postpartum Dual-energy X-ray absorptiometry (DXA) scan.

1
2
3
4 *Offspring growth:* Head circumference, length, and weight is measured at birth, and by general
5 practitioners at five weeks, five months, and 12 months postpartum. Participants receive an electronic
6 questionnaire and fill out the anthropometric data along with information on offspring dietary habits
7 and vaccine-status. *Parental mental wellbeing* is assessed 6-8 weeks after birth. Both parents or holders
8 of custody receive a questionnaire consisting of the Edinburgh Postnatal Depression Score, and
9 Gotland Depression Scale which are combined as a screening tool for postnatal depression (89–92) in
10 Danish postnatal care. *Psychomotor development of the offspring* is assessed by the validated Ages and
11 Stages Questionnaire 3 (ASQ-3), which is administered electronically to participants 12 months after
12 the due date. ASQ-3 pinpoints developmental progress in the fields of communication, gross motor,
13 fine motor, problem-solving, and personal-social skills. The administration of ASQ-3 relative to due
14 and not to birth date aims to correct for variance in cognitive and motor skills due to premature birth.
15 *Offspring physical activity* is assessed for seven days by an infant activity tracker (Actigraph GT3X+)
16 12 months after the due date. The tracker detects level, intensity, and pattern of physical activity.
17
18

22 *Analyses of blood, placenta and breast milk samples*

23 *Plasma metabolites and hormones* are assessed in maternal and paternal venous blood. The blood
24 samples will be analysed for concentrations of glucose, cholesterol (total, high and low density),
25 triglyceride, insulin, free fatty acids, amino acids, interleukin-6, and C-reactive protein. Venous blood
26 is obtained from the umbilical cord within 30 min after delivery of the placenta. The blood will be
27 analysed for concentrations of glucose, cholesterol (total, high and low density), triglyceride, insulin, c-
28 peptide, free fatty acids, amino acids, adiponectin, and leptin. Furthermore, epigenetic profiling at the
29 level of *DNA methylation* will be performed in maternal, paternal, and umbilical cord blood
30 mononuclear cells. Bioinformatic comparison of DNA methylomes from parents and offspring will
31 infer on the DNA methylation marks that are modulated by maternal exercise and transmitted to the
32 offspring. Information on DNA methylomes from each parent will allow us to distinguish between
33 maternally and paternally epigenetic profiles transmitted to the offspring. Principal component analyses
34 will be used to identify the specific metabolic or anthropometric features of the mother that are
35 associated with a specific DNA methylation footprint transmitted to the offspring. *Placental function* is
36 assessed from samples taken within 30 min after delivery of the placenta. The samples are immediately
37 frozen on dry ice and stored at -80 °C. Analyses will include RNA-seq, non-targeted metabolomics,
38 RT-qPCR, Western blot, histology, and immunohistochemistry. *Breast milk* is obtained from a single
39 feed at the day of visit 5 and stored at -80 °C for later metabolomic and lipidomic analyses.
40
41
42
43
44
45

46 *Process evaluation of interventions*

47 A process evaluation is made using quantitative and qualitative methods to provide insight into
48 mechanisms through which interventions bring about change, assess fidelity and quality of
49 implementation, clarify causal mechanisms, and identify contextual factors associated with variations
50 in outcomes (93–95). Integrating process evaluations alongside outcome data is recommended by the
51 UK Medical Research Council guidelines in order to develop and evaluate complex interventions to
52 improve the interpretation of the outcomes, design more effective interventions, and apply
53
54
55
56

1
2
3
4 interventions appropriately across groups and settings by understanding the implementation and
5 functioning of interventions in a given context (94,96). The RE-AIM (Reach, Effectiveness, Adoption,
6 Implementation, and Maintenance) framework is used to improve reporting on key issues related to the
7 implementation and external validity of FitMum RCT (97).
8
9

10 *Personal understandings of physical activity*

11 The qualitative dataset is comprised of 220 short standardised screening interviews, 30 semi-structured
12 interviews, 70 observations, five sets of auto-ethnographies, visual material, as well as drop-out and
13 follow-up interviews. This sub-project will explore the physical and mental health and wellbeing of the
14 participants, their social relations, PA levels, and their experience of pregnancy to identify the
15 challenges and barriers of PA during pregnancy. Personal understandings of PA in the everyday life of
16 participants are determined at inclusion, GA week 34, and one year postpartum, in approximately ten
17 participants from each of the three study groups.
18
19
20

21 **Changes during the COVID-19 pandemic**

22 Due to the COVID-19 pandemic (present in Denmark from March 11th 2020), supplies of interventions
23 (EXE and MOT) and visits are periodically changed. During the lockdown periods in spring and
24 autumn 2020, all interventions and visits (except birth) are converted into online versions using Zoom
25 Cloud Meetings or telephone. In EXE, the swimming pool sessions are replaced with online land
26 exercises. From March 11th 2020, all land exercise sessions consist of 30 min of aerobic exercise where
27 the participants exercise on their own (e.g. biking, power-walking, dancing, aerobics) followed by 30
28 min of supervised online group resistance training. All individual and group MOT sessions are held
29 online.
30
31
32

33 As much data as possible is collected during the pandemic, but some clinical data have not been
34 possible to obtain in all participants due to limitations on non-urgent visits to the hospital. No blood
35 samples are obtained at the virtual 'visits', women are weighed at home, and symphysis-fundal height
36 measurements are not obtained. No doubly labelled water is administered at the virtual 'visit' 2. The
37 participant's body weight at visit 4 is noted by the midwives on the day of giving birth, but biological
38 samples are not collected. No DXA-scans or breast milk samples are collected at 'visit' 5.
39
40
41
42

43 **Data management and analysis**

44 **Data management**

45 The activity tracker data are collected by Fitabase, which regularly backs up the data. A participant
46 who does not synchronize the tracker for seven days or more is reminded by email, text message, or
47 phone call. All tracker data are exported from Fitabase to R (98) for data analysis. Tracker data are
48 utilized to calculate non-wear time; a week is included in the analysis if the week has four or more days
49 with complete data. A day that has six hours or more of non-wear time is excluded and considered a
50 missing day. An electronic case report form (e-CRF) is utilized to collect all clinical data related to the
51 trial. Data are stored in coded form according to the rules of the Danish Data Protection Agency.
52 Personal data processing complies with the Act on Processing of Personal Data. Data is owned by
53
54
55
56

1
2
3
4 NOH and University of Copenhagen. Use of data generated in FitMum RCT in new contexts must be
5 agreed and approved by the Steering group. Technical University of Denmark and Aarhus University
6 must have access to the data they have collected and are free to use it in new contexts. The e-CRF is
7 completed by the investigators at the time of the participant's visits at NOH so that it always reflects
8 the latest observations of the participant. Data will be stored for 25 years, after which they will be
9 transferred to the Danish National Archives "Rigsarkivet" in an anonymized format.
10
11

12 **Sample size**

13 FitMum RCT has been powered to detect an overall significant difference in the primary outcome
14 between the three groups as well as a significant difference between the two intervention groups (EXE
15 vs. MOT) with average activity levels of 60 (CON), 210 (EXE) and 150 (MOT) min/week. The
16 standard deviation was set at 116 min/week and based on the results from Oostdam et al. (51). The
17 required sample size is determined to obtain a power of 80% with a family-wise significance level of
18 5%. The sample size calculation showed that the required number of participants is 35 in CON and 70
19 in each of the two intervention groups due to the randomization ratio of 1:2:2 to CON, EXE, and MOT,
20 respectively. Based on an expected lost-to-follow-up rate of 20%, as seen in similar exercise studies in
21 pregnant women (28,32,33,51), we plan to include 44 participants in CON and 88 participants in each
22 of the two intervention groups, making a total of 220 participants.
23
24
25
26

27 **Statistical methods**

28 Data analyses of both primary and secondary outcomes will be performed using intention-to-treat
29 analyses. In addition, a dose-response model will be estimated to quantify the relationship between
30 adherence to the intervention (proportion of attendances in the planned EXE and MOT sessions,
31 respectively) and the activity level. Moreover, analyses describing associations between the level of
32 physical activity (as measured by the activity tracker) and the secondary and additional outcomes will
33 be performed. Baseline data will be reported as averages and standard deviations (medians and
34 interquartile ranges) or frequencies and proportions as appropriate. No interim analyses will be
35 performed on the primary and secondary outcomes. The analysis of the primary outcome will be
36 performed using a linear model with the randomization group as a categorical covariate and with
37 adjustment for baseline PA level. Hypothesis tests will be performed using likelihood ratio tests.
38 Statistical analysis will be conducted using R (98). Analyses of the primary outcome will be performed
39 by a statistician blinded from the intervention allocations. Investigators will perform analyses of
40 baseline data and secondary and additional outcomes under the supervision of a statistician. A full
41 statistical analysis plan is published in clinicaltrials.gov (99).
42
43
44
45
46
47

48 **Trial status**

49 The recruitment of participants began in September 2018 and ended in October 2020. Data collection
50 of the primary outcome is expected to be complete in spring 2021. Full data collection is expected to be
51 complete in 2022.
52
53
54
55
56

Ethics and dissemination

The FitMum study adheres to the principles of the Helsinki declaration. The study is approved by the Danish National Committee on Health Research Ethics (# H-18011067) and the Danish Data Protection Agency (# VD-2018-336).

All participants consent in written form before inclusion and are informed that participation in the FitMum study is voluntary. Participants are informed that they may withdraw from the study at any time, and that withdrawal of consent will not affect any subsequent pregnancy and delivery processes at NOH. The participant has time to ask questions and is allowed 24 hours to deliberate on study participation before the obtainment of written informed consent.

FitMum RCT is designed based on recommendations of appropriate PA during pregnancy (14,45,100,101), and although anatomic and physiological changes occur during pregnancy, PA during an uncomplicated pregnancy is safe (14,22,29,40,60,102–105). All information about adverse events and serious adverse events are documented consecutively and will be reported. Participants will be discontinued from the intervention if they are at risk of preterm birth, if a cervical length below 25 mm is measured, if serious obstetric or medical complications occur, if investigators' assessment reveals that continuation in the trial would be detrimental to the participant's well-being, or if intolerable adverse events occur.

The FitMum study will provide evidence-based knowledge that can contribute to improving national and international recommendations of PA during pregnancy and to new, effective, and simple guidance to implement health technology-supported exercise programs to pregnant women. Based on the results and process evaluation, the knowledge and tools from the FitMum study can be transformed into initiatives in municipalities and hospitals to improve the health and quality of life for both mother and child, and can be used for preventing the development of lifestyle-related diseases across generations.

Findings will be submitted for publication in peer-reviewed scientific journals and disseminated at national and international conferences. In addition, results will be disseminated to the public in relevant media and to health professionals via science theatre performances.

Discussion

The FitMum study aims to evaluate the effects of structured supervised exercise training and motivational counselling supported by health technology on PA level during pregnancy to generate evidence about *how* to implement PA in everyday life in healthy pregnant women. Previous studies have investigated the effect of different lifestyle interventions on various health outcomes in normal weight (23,24,26,28,50–57), overweight, and obese pregnant women (20,21,32,33,58–61). However, none of these studies have focused primarily on investigating the effect of PA interventions on actual PA level determined by novel objective methods. In addition, the FitMum study compares the effect of two very different PA interventions to explore strategies to implement PA programs into pregnant women's everyday life. Moreover, offspring of FitMum participants will be studied for one year after

1
2
3
4 birth, whereby knowledge on the effect of PA during pregnancy on offspring health will be obtained. A
5 limitation of the study is that the true effect of motivational counselling is not identified, as technology
6 is an integral part of the MOT intervention.
7

8
9 Consumer-based wearable activity trackers tend to increase PA level when they are used as an
10 intervention tool or as part of an intervention (106). Activity trackers are often relatively light weight,
11 comfortable to wear, and rechargeable (107). In addition, using an activity tracker to measure PA
12 during pregnancy is feasible, recommended (108), and has a reasonable compliance rate during
13 pregnancy and after giving birth (109). However, there are some challenges and limitations of using
14 activity trackers in a long-term intervention study. Firstly, the participants must recharge the device and
15 synchronize their data approximately once per week, which burdens participants and challenges
16 adherence and compliance. Secondly, we cannot control the interaction of CON participants with the
17 tracker. Thirdly, the main goal for the tracker's design is a comfortable wear, yet wearing the tracker
18 for extended periods of time may cause skin irritation and discomfort (110). Moreover, the
19 unavailability of the raw data and algorithms used by the manufacturer creates a limitation in the
20 validation of PA metrics (107). Therefore, measuring PA by a variety of methods, and comparing these
21 methods with the doubly labelled water technique (a gold standard method), will be used in order to
22 obtain comprehensive measures of PA behaviours in FitMum participants.
23
24
25
26
27

28 **Conflicts of interest**

29 The authors declare that they have no conflicts of interest.
30

31 **Acknowledgements**

32 We would like to thank the technical staff, especially Susanne Månsson, from the Clinical Research
33 Unit, Department of Research, NOH, for their contribution in planning the practical work involved in
34 the collection of data.
35
36

37 **Funding**

38 The FitMum study has been financially supported by the Independent Research Fund Denmark (8020-
39 00353B and 0218-00014B), TrygFonden (128509), Copenhagen Center for Health Technology
40 (061017), Beckett-Fonden (17-2-0883), Aase and Ejnar Danielsens Fond (10-002052), and Familien
41 Hede Niensens Fond (2017-1142).
42
43
44

45 **Authors' contribution**

46 BS initiated the FitMum study together with LT and is the principal investigator of FitMum RCT. EL is
47 the clinical trial manager. A steering group consisting of BS, EL, TDC, JEL and HTM oversees trial
48 status and progression. CBR, SdPK and BS led the protocol development with contribution from SA,
49 ADA, JB, TDC, SM, AKJ, GT, APJ, JEL, GvH, EA, RB, OHM, HTM, LT, and EL. CBR, SdPK, SA,
50 ADA, JB, TDC, SM, EL and BS constitute the clinical core group that guides the practical performance
51 of FitMum RCT. CBR, SdPK and ADA conduct intervention activities together with research assistants
52 and master's students. CBR, SdPK, SA and ADA will perform most of the data analysis along with
53
54
55
56

AKJ. Analyses of the primary outcome will be performed by AKJ. All authors read, contributed to and approved the final version of the manuscript.

References

1. Craike M, Hill B, Gaskin CJ, Skouteris H. Interventions to improve physical activity during pregnancy: a systematic review on issues of internal and external validity using the RE-AIM framework. *BJOG An Int J Obstet Gynaecol*. 2017;124(4):573–83.
2. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. Interventions to reduce or prevent obesity in pregnant women: A systematic review. *Health Technol Assess (Rockv)*. 2012;16(31):1–8.
3. World Health Organisation (WHO). Good Maternal Nutrition. The best start in life. 2016;
4. Adamo KB, Ferraro ZM, Brett KE. Can we modify the intrauterine environment to halt the intergenerational cycle of obesity? *Int J Environ Res Public Health*. 2012;9(4):1263–307.
5. Jelsma JGM, Van Leeuwen KM, Oostdam N, Bunn C, Simmons D, Desoye G, et al. Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study. *J Pregnancy*. 2016;1–11.
6. Hill B, McPhie S, Moran LJ, Harrison P, Huang TTK, Teede H, et al. Lifestyle intervention to prevent obesity during pregnancy: Implications and recommendations for research and implementation. *Midwifery*. 2017;49(May 2016):13–8.
7. Bønnelycke J, Sandholdt CT, Jespersen AP. Household collectives: resituating health promotion and physical activity. *Sociol Heal Illn*. 2019;41(3):533–48.
8. Borodulin K, Evenson KR, Herring AH. Physical activity patterns during pregnancy through postpartum. *BMC Womens Health*. 2009;9(1):32.
9. Santo EC, Forbes PW, Oken E, Belfort MB. Determinants of physical activity frequency and provider advice during pregnancy. 2017;1–11.
10. Hegaard HK, Damm P, Hedegaard M, Henriksen TB, Ottesen B, Dykes AK, et al. Sports and leisure time physical activity during pregnancy in nulliparous women. *Matern Child Health J*. 2011;15(6):806–13.
11. Owe KM, Nystad W, Bø K. Correlates of regular exercise during pregnancy: The Norwegian Mother and Child Cohort Study. *Scand J Med Sci Sport*. 2009;19(5):637–45.
12. Richardsen KR, Falk RS, Jenum AK, Mørkrid K, Martinsen EW, Ommundsen Y, et al. Predicting who fails to meet the physical activity guideline in pregnancy: A prospective study of objectively recorded physical activity in a population-based multi-ethnic cohort. *BMC Pregnancy Childbirth*. 2016;16(1):1–11.
13. Barrès R, Zierath JR. The role of diet and exercise in the transgenerational epigenetic landscape of T2DM. *Nat Rev Endocrinol*. 2016;12(8):441–51.
14. Committee on Obstetric Practice. Committee Opinion: Physical Activity and Exercise During

- Pregnancy and the Postpartum Period. *Am Coll Obstet Gynecol*. 2015;650:1–8.
15. Evenson KR, Barakat R, Brown WJ, Dargent-Molina P, Haruna M, Mikkelsen EM, et al. Guidelines for Physical Activity during Pregnancy: Comparisons From Around the World. *Am J Lifestyle Med*. 2014;8(2):102–21.
 16. Perales M, Artal R LA. Exercise During Pregnancy. *JAMA*. 2017;317(11):1113–4.
 17. Moyer C, Reoyo OR, May L. The Influence of Prenatal Exercise on Offspring Health: A Review. 2016;9:37–42.
 18. U.S. Department of Health and Human Services. 2018 Physical Activity Guidelines Advisory Committee Scientific Report To the Secretary of Health and Human. 2018 Phys Act Guidel Advis Comm Sci Report To Secr Heal Hum Serv [Internet]. 2018; Available from: https://health.gov/paguidelines/second-edition/report/pdf/PAG_Advisory_Committee_Report.pdf
 19. Mottola MF, Davenport MH, Ruchat SM, Davies GA, Poitras VJ, Gray CE, et al. 2019 Canadian guideline for physical activity throughout pregnancy. *Br J Sports Med*. 2018;52(21):1339–46.
 20. Ruiz JR, Perales M, Pelaez M, Lopez C, Lucia A, Barakat R. Supervised exercise-based intervention to prevent excessive gestational weight gain: A randomized controlled trial. *Mayo Clin Proc*. 2013;88(12):1388–97.
 21. Leung Hui A, Back L, Ludwig S, Gardiner P, Sevenhuysen G, Dean HJ, et al. Effects of lifestyle intervention on dietary intake, physical activity level, and gestational weight gain in pregnant women with different pre-pregnancy Body Mass Index in a randomized control trial. *BMC Pregnancy Childbirth*. 2014;14(331):1–9.
 22. Wiebe HW, Boulé NG, Chari R, Davenport MH. The Effect of Supervised Prenatal Exercise on Fetal Growth. *Obstet Gynecol*. 2015;125(5):1185–94.
 23. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2015;3(10):767–77.
 24. Harrison CL, Lombard CB, Strauss BJ, Teede HJ. Optimizing healthy gestational weight gain in women at high risk of gestational diabetes: A randomized controlled trial. *Obesity*. 2013;21(5):904–9.
 25. Vinter CA, Jensen DM, Ovesen P, Beck-nielsen H, Jørgensen JS. The LiP (Lifestyle in Pregnancy) Study. *Diabetes Care*. 2011;34:2502–7.
 26. Renault KM, Nørgaard K, Nilas L, Carlsen EM, Cortes D, Pryds O, et al. The Treatment of Obese Pregnant Women (TOP) study: A randomized controlled trial of the effect of physical activity intervention assessed by pedometer with or without dietary intervention in obese pregnant women. *Am J Obstet Gynecol*. 2014;210:134.e1-9.
 27. Russo LM, Nobles C, Ertel KA, Chasan-Taber L, Whitcomb BW. Physical Activity Interventions in Pregnancy and Risk of Gestational Diabetes Mellitus A Systematic Review and Meta-analysis. *Obstet Gynecol*. 2015;125(3):576–82.

- 1
- 2
- 3
- 4 28. Wang C, Wei Y, Zhang X, Zhang Y, Xu Q, Sun Y, et al. A randomized clinical trial of exercise
- 5 during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in
- 6 overweight and obese pregnant women. *Am J Obstet Gynecol*. 2017;1–30.
- 7
- 8 29. Di Mascio D, Magro-Malosso ER, Saccone G, Marhefka GD, Berghella V. Exercise during
- 9 pregnancy in normal-weight women and risk of preterm birth: a systematic review and meta-
- 10 analysis of randomized controlled trials. *American Journal of Obstetrics and Gynecology*. 2016.
- 11 p. 561–71.
- 12
- 13 30. Sanabria-Martinez G, Garcia-Hermoso A, Poyatos-Leon R, Alvarez-Bueno C, Sanchez-Lopez
- 14 M, Martinez-Vizcaino V. Effectiveness of physical activity interventions on preventing
- 15 gestational diabetes mellitus and excessive maternal weight gain: A meta-analysis. *BJOG An Int*
- 16 *J Obstet Gynaecol*. 2015;122(9):1167–74.
- 17
- 18 31. Koivusalo SB, Rönö K, Klemetti MM, Roine RP, Lindström J, Erkkola M, et al. Gestational
- 19 Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes
- 20 Prevention Study (RADIEL): A Randomized Controlled Trial. *Diabetes Care*. 2016;39(1):24–30.
- 21
- 22 32. Barakat R, Perales M, Cordero Y, Bacchi M, Mottola MF. Influence of Land or Water Exercise
- 23 in Pregnancy on Outcomes: A Cross-sectional Study. *Med Sci Sports Exerc*. 2017;49(7):1397–
- 24 403.
- 25
- 26 33. Backhausen MG, Tabor A, Albert H, Rosthøj S, Damm P, Hegaard HK. The effects of an
- 27 unsupervised water exercise program on low back pain and sick leave among healthy pregnant
- 28 women - A randomised controlled trial. *PLoS One*. 2017;12(9):e0182114.
- 29
- 30 34. Barakat R, Pelaez M, Lopez C, Montejo R, Coteron J. Exercise during pregnancy reduces the
- 31 rate of cesarean and instrumental deliveries: results of a randomized controlled trial. *J Matern*
- 32 *Neonatal Med*. 2012;25(11):2372–6.
- 33
- 34 35. Nielsen EN, Andersen PK, Hegaard HK, Juhl M. Mode of Delivery according to Leisure Time
- 35 Physical Activity before and during Pregnancy: A Multicenter Cohort Study of Low-Risk
- 36 Women. *J Pregnancy*. 2017;2017:1–8.
- 37
- 38 36. Dumith SC, Domingues MR, Mendoza-Sassi R a, Cesar J a. Physical activity during pregnancy
- 39 and its association with maternal and child health indicators. *Rev Saude Publica*.
- 40 2012;46(2):327–33.
- 41
- 42 37. Owe KM, Nystad W, Stigum H, Vangen S, Bø K. Exercise during pregnancy and risk of
- 43 cesarean delivery in nulliparous women: a large population-based cohort study Katrine.
- 44 2016;0(December 2016):1–6.
- 45
- 46 38. Ferrari N, Bae-Gartz I, Bauer C, Janoschek R, Koxholt I, Mahabir E, et al. Exercise during
- 47 pregnancy and its impact on mothers and offspring in humans and mice. *J Dev Orig Health Dis*.
- 48 2017;1–14.
- 49
- 50 39. Huang L, Fan L, Ding P, He Y-H, Xie C, Niu Z, et al. Maternal exercise during pregnancy
- 51 reduces the risk of preterm birth through the mediating role of placenta. *J Matern Neonatal Med*.
- 52 2017;7058(September):1–21.
- 53
- 54 40. Magro-Malosso ER, Saccone G, Di Mascio D, Marhefka GD, Berghella V. Exercise during
- 55
- 56
- 57
- 58
- 59
- 60

- pregnancy risk of preterm birth in overweight and obese women: A systematic review and meta-analysis of randomized controlled trials. *Acta Obstet Gynecol Scand.* 2017;215(5):561–71.
41. Pomeroy J, Renström F, Gradmark AM, Mogren I, Persson M, Bluck L, et al. Maternal physical activity and insulin action in pregnancy and their relationships with infant body composition. *Diabetes Care.* 2013;36(2):267–9.
 42. Harrod CS, Chasan-Taber L, Reynolds RM, Fingerlin TE, Glueck DH, Brinton JT, et al. Physical Activity in Pregnancy and Neonatal Body Composition: The Healthy Start Study. *Obs Gynecol.* 2014;124(1):257–64.
 43. Clapp JF. Influence of Endurance Exercise and Diet on Human Placental Development and Fetal Growth. *Placenta.* 2006;27(6–7):527–34.
 44. Jackson MR, Gott P, Lye SJ, Ritchie JW, Clapp JF. The effects of maternal aerobic exercise on human placental development: placental volumetric composition and surface areas. *Placenta.* 1995;16(2):179–91.
 45. The Danish Health Authorities. Recommendations for pregnant women [Internet]. 2014. Available from: <https://www.sst.dk/en/health-and-lifestyle/physical-activity/recommendations/pregnant-women>
 46. Broberg L, Ersbøll AS, Backhausen MG, Damm P, Tabor A, Hegaard HK. Compliance with national recommendations for exercise during early pregnancy in a Danish cohort. *BMC Pregnancy Childbirth.* 2015;15:317.
 47. Weir Z, Bush J, SC R, McParlin C, Rankin J, Bell R. Physical activity in pregnancy: a qualitative study of the beliefs of overweight and obese pregnant women. *BMC Pregnancy Childbirth.* 2010;10(18):1–7.
 48. Bauer C, Graf C, Platschek AM, Strüder HK, Ferrari N. Reasons, Motivational Factors and Perceived Personal Barriers to Engagement in Physical Activity During Pregnancy Vary Within the BMI Classes - The Prenatal Prevention Project Germany. *J Phys Act Heal.* 2017;32:1–44.
 49. Lindqvist M, Persson M, Mogren I. “Longing for individual recognition” – Pregnant women’s experiences of midwives’ counselling on physical activity during pregnancy. *Sex Reprod Healthc.* 2018;15:46–53.
 50. Hawkins M, Chasan-Taber L, Marcus B, Stanek E, Braun B, Ciccolo J, et al. Impact of an exercise intervention on physical activity during pregnancy: The behaviors affecting baby and you study. *Am J Public Health.* 2014;104(10):e74–81.
 51. Oostdam N, Van Poppel MNM, Wouters MG AJ, Eekhoff EMW, Bekedam DJ, Kuchenbecker WKH, et al. No effect of the FitFor2 exercise programme on blood glucose, insulin sensitivity, and birthweight in pregnant women who were overweight and at risk for gestational diabetes: Results of a randomised controlled trial. *BJOG An Int J Obstet Gynaecol.* 2012;119:1098–107.
 52. Seneviratne S, Jiang Y, Derraik J, Mccowan L, Parry G, Biggs J, et al. Effects of antenatal exercise in overweight and obese pregnant women on maternal and perinatal outcomes: a randomised controlled trial. *BJOG.* 2016;123:588–97.
 53. Ussher M, Lewis S, Aveyard P, Manyonda I, West R, Lewis B, et al. Physical activity for

- 1
2
3
4 smoking cessation in pregnancy: randomised controlled trial. *BMJ*. 2015;350(h2145):1–10.
5
6 54. Gaston A, Prapavessis H. Using a combined protection motivation theory and health action
7 process approach intervention to promote exercise during pregnancy. *J Behav Med*.
8 2014;37(2):173–84.
9
10 55. Vinter CA, Jensen DM, Ovesen P, Beck-Nielsen H, Jørgensen JS. The LiP (Lifestyle in
11 Pregnancy) study: A randomized controlled trial of lifestyle intervention in 360 obese pregnant
12 women. *Diabetes Care*. 2011;34:2502–7.
13
14 56. Kong KL, Campbell CG, Foster RC, Peterson AD, Lanningham-Foster L. A pilot walking
15 program promotes moderate-intensity physical activity during pregnancy. *Med Sci Sports Exerc*.
16 2014;46:2–71.
17
18 57. Smith KM. The Blossom Project Online: Use of a behaviorally-based website to promote
19 physical activity and prevent excessive gestational weight gain in previously sedentary pregnant
20 women. ProQuest Dissertations and Theses. 2014.
21
22 58. Cavalcante SR, Cecatti JG, Pereira RI, Baciuk EP, Bernardo AL, Silveira C. Water aerobics II:
23 maternal body composition and perinatal outcomes after a program for low risk pregnant
24 women. *Reprod Health*. 2009;6(1):1–7.
25
26 59. Haakstad L, Bo K. Exercise in pregnant women and birth weight: a randomized controlled trial.
27 *BMC Pregnancy Childbirth*. 2011;11(1):1–7.
28
29 60. Tomic V, Sporis G, Tomic J, Milanovic Z, Zigmundovac-Klaic D, Pantelic S. The effect of
30 maternal exercise during pregnancy on abdominal fetal growth. *Croat Med J*. 2013;54:362–8.
31
32 61. De Oliveria Melo AS, Silva JLP, Tavares JS, Barros VO, Leite DFB, Amorim MMR. Effect of a
33 physical exercise program during pregnancy on uteroplacental and fetal blood flow and fetal
34 growth: A randomized controlled trial. *Obstet Gynecol*. 2012;120(2 PART 1):302–10.
35
36 62. Currie S, Sinclair M, Murphy MH, Madden E, Dunwoody L, Liddle D. Reducing the Decline in
37 Physical Activity during Pregnancy: A Systematic Review of Behaviour Change Interventions.
38 *PLoS One*. 2013;8(6):1–12.
39
40 63. Pearce E, Evenson K. Strategies to promote physical activity during pregnancy. *Am J Lifestyle*
41 *Med*. 2013;7(1):1–19.
42
43 64. Borg GAV. Psychophysical bases of perceived exertion. 1982.
44
45 65. Bennett G. Miller, W. R. and Rollnick, S. (1991) Motivational interviewing: Preparing people to
46 change addictive behavior. New York: Guilford Press, 1991. Pp. xvii + 348. £24.95 hardback,
47 £11.50 paper. ISBN 0–89862–566–1. *J Community Appl Soc Psychol* [Internet]. 1992 Nov 1
48 [cited 2020 Aug 3];2(4):299–300. Available from:
49 <http://doi.wiley.com/10.1002/casp.2450020410>
50
51 66. Markland D, Ryan RM, Tobin VJ, Rollnick S. Motivational Interviewing and Self-
52 Determination Theory. *J Soc Clin Psychol*. 2005;24(6):811–31.
53
54 67. Michie S, Ashford S, Sniehotta FF, Dombrowski SU, Bishop A, French DP. A refined taxonomy
55 of behaviour change techniques to help people change their physical activity and healthy eating
56
57
58
59

- behaviours: The CALO-RE taxonomy. *Psychol Heal*. 2011;26(11):1479–98.
68. De Vries HJ, Kooiman TJM, van Ittersum MW, van Brussel M, de Groot M. Do activity monitors increase physical activity in adults with overweight or obesity? A systematic review and meta-analysis. *Obesity*. 2016;24(10):2078–91.
69. Cadmus-bertram LA, Marcus BH, Patterson RE, Parker BA, Morey BL. Randomized Trial of a Fitbit-Based Physical Activity Intervention for Women. *Am J Prev Med*. 2015;49(3):414–8.
70. Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G, Freedson PS. Development and validation of a pregnancy physical activity questionnaire. *Med Sci Sports Exerc*. 2004;36(10):1750–60.
71. Santini De Oliveira C, Dos Santos Imakawa T, Christine Dantas Moises E. Physical Activity during Pregnancy: Recommendations and Assessment Tools. *Rev Bras Ginecol Obs*. 2017;39:424–32.
72. Schuster S, Sklempe Kokic I, Sindik J. Measuring Physical Activity in Pregnancy Using Questionnaires: a Meta-Analysis. *Acta Clin Croat*. 2016;55(3):440–51.
73. Holmberg Krøner F, de Place Knudsen S, Borup Roland C, Abdulaziz Alomairah S, Molsted S. Validity and reliability of the Danish version of the pregnancy physical activity questionnaire to assess levels of physical activity during pregnancy. 2020 [cited 2020 Dec 9]; Available from: <https://www.tandfonline.com/action/journalInformation?journalCode=ijmf20>
74. Abeysekera M V, Morris JA, O ’sullivan AJ. Techniques to measure free-living energy expenditure during pregnancy – A guide for clinicians and researchers. *Obstet Med*. 2014;7(2):60–5.
75. Van Hees VT, Renström F, Wright A, Gradmark A, Catt M, Chen KY, et al. Estimation of daily energy expenditure in pregnant and Non-Pregnant women using a Wrist-Worn Tri-Axial accelerometer. *PLoS One*. 2011;6(7):1–10.
76. Lof M, Forsum E. Activity pattern and energy expenditure due to physical activity before and during pregnancy in healthy Swedish women. *Br J Nutr*. 2006;95(2):296–302.
77. Wong WW, Roberts SB, Racette SB, Das SK, Redman LM, Rochon J, et al. The Doubly Labeled Water Method Produces Highly Reproducible Longitudinal Results in. *J Nutr*. 2014;144:777–83.
78. RAND Corporation. 36-Item Short Form Survey Instrument (SF-36). 2016;5–10.
79. Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated. SF-36v2 Health Survey. 2004;
80. Jomeen J, Martin CR. The factor structure of the SF-36 in early pregnancy. *J Psychosom Res*. 2005 Sep;59(3):131–8.
81. Bland HW, Melton BF, Marshall ES, Nagle JA. Measuring Exercise Self-Efficacy in Pregnant Women: Psychometric Properties of the Pregnancy-Exercise Self-Efficacy Scale (P-ESES). *J Nurs Meas*. 2013 Dec 1;21(3):349–59.
82. Bendix EJ, Holmberg Krøner F, De Place Knudsen S, Bendix JM, Molsted S. Cross-cultural

- adaption, translation and reliability tests of the Danish version of the Pregnancy Exercise Self-Efficacy Scale. *Sex Reprod Healthc* [Internet]. 2020 Dec 1 [cited 2020 Aug 11];26(May):100542. Available from: <https://doi.org/10.1016/j.srhc.2020.100542>
83. Mullan E, Markland D, Ingledew DK. A graded conceptualisation of self-determination in the regulation of exercise behaviour: Development of a measure using confirmatory factor analytic procedures. Vol. 23, ~) Pergamon Person. individ. Diff. 1997.
84. Mullan E, Markland D, Mullan E. Variations in Self-Determination Across the Stages of Change for Exercise in Adults. Vol. 21, Motivation and Emotion. Markland & Hardy; 1997.
85. Markland D, Tobin V. A Modification to the Behavioural Regulation in Exercise Questionnaire to Include an Assessment of Amotivation. *J Sport Exerc Psychol*. 2004 Jun;26(2):191–6.
86. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index : A New Instrument Psychiatric Practice and Research. *Psychiatry Res*. 1989;28:193–213.
87. University of Pittsburgh. Pittsburgh Sleep Quality Index (PSQI). 1988;(3):6.
88. Qiu C, Gelaye B, Zhong Q-Y, Enquobahrie DA, Frederick IO, Williams MA. Construct validity and factor structure of the Pittsburgh Sleep Quality Index among pregnant women in a Pacific-Northwest cohort. *Sleep Breath*. 2016;20(1):293–301.
89. Cox JL (John L, Holden J. Perinatal mental health : a guide to the Edinburgh Postnatal Depression Scale (EPDS). Gaskell; 2003. 125 p.
90. Zierau F, Bille A, Rutz W, Bech P. The Gotland Male Depression Scale: A validity study in patients with alcohol use disorder. *Nord J Psychiatry* [Internet]. 2002 Jan 12 [cited 2019 Apr 11];56(4):265–71. Available from: <http://www.tandfonline.com/doi/full/10.1080/08039480260242750>
91. Magovcevic M, Addis ME. The Masculine Depression Scale: Development and psychometric evaluation. *Psychol Men Masc* [Internet]. 2008 Jul [cited 2019 Apr 11];9(3):117–32. Available from: <http://doi.apa.org/getdoi.cfm?doi=10.1037/1524-9220.9.3.117>
92. Madsen SA. Spædbarnet i faderens verden (Infants' within the world of the father). *Psyke & Logos* [Internet]. 2008;29(2):669–87. Available from: <https://tidsskrift.dk/psyke/article/view/8503>
93. Craig P. Developing and evaluating complex interventions.
94. Moore G, Audrey S, Barker M, Bond L, Bonell C, Cooper C, et al. Process evaluation in complex public health intervention studies: the need for guidance. *J Epidemiol Community Health*. 2014 Feb;68(2):101–2.
95. Hoffmann TC, Erueti C, Glasziou PP. Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. *BMJ*. 2013 Sep;347:f3755.
96. F. Moore G, Raisanen L, Moore L, Ud Din N, Murphy S. Mixed-method process evaluation of the Welsh National Exercise Referral Scheme. *Health Educ*. 2013 Oct;113(6):476–501.
97. Glasgow RE, Vogt TM, Boles SM. Evaluating the Public Health Impact of Health Promotion Interventions: The RE-AIM Framework. 1999 [cited 2018 Mar 8];89(9). Available from:

- 1
2
3
4 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508772/pdf/amjph00009-0018.pdf>
- 5
- 6 98. R Core Team (2020). R: A language and environment for statistical computing. R Foundation
7 for Statistical Computing, Vienna, Austria. [Internet]. Available from: <https://www.r-project.org/>
8
- 9 99. Statistical Analysis Plan (SAP) for the FitMum randomized controlled trial [Internet]. Statistical
10 Analysis Plan (SAP) for the FitMum randomized controlled trial. 2020. Available from:
11 https://clinicaltrials.gov/ProvidedDocs/30/NCT03679130/SAP_000.pdf
12
- 13 100. UK Chief Medical Officers. UK Chief Medical Officers Recommendations 2017: Physical
14 Activity in Pregnancy. 2017.
- 15 101. UK Chief Medical Officers. UK Chief Medical Officers Recommendations 2017: Physical
16 Activity in Pregnancy, guidance. 2017;1–7.
17
- 18 102. Verdiere S, Guinhoya BC, Salerno D, Deruelle P. Should physical activity be contraindicated
19 during pregnancy in relation to its potentially related risks? 2017;45:104–11.
20
- 21 103. Melo ASDO, Silva JLP, Tavares JS, Barros VO, Leite DFB, Amorim MMR. Effect of a Physical
22 Exercise Program During Pregnancy on Uteroplacental and Fetal Blood Flow and Fetal Growth.
23 2012;120(2):302–10.
24
- 25 104. Rêgo AS, Alves MTSS de B e, Batista RFL, Ribeiro CCC, Bettiol H, Cardoso VC, et al.
26 Physical activity in pregnancy and adverse birth outcomes. *Cad Saude Publica*. 2016;32(11):1–
27 10.
28
- 29 105. Charlesworth S, Foulds HJ a, Burr J, Bredin SSD. Evidence-based risk assessment and
30 recommendations for physical activity clearance: pregnancy. *Appl Physiol Nutr Metab*.
31 2011;36(S1):S154–89.
32
- 33 106. Brickwood K, Hons B, Watson G, Brien JO, Williams AD. Consumer-Based Wearable Activity
34 Trackers Increase Physical Activity Participation : Systematic Review and Meta-Analysis
35 Corresponding Author : 2019;7(4).
36
- 37 107. Wright SP, Hall Brown TS, Collier SR, Sandberg K. How consumer physical activity monitors
38 could transform human physiology research. *Am J Physiol - Regul Integr Comp Physiol*.
39 2017;312:R358–67.
40
- 41 108. Guérin E, Ferraro ZM, Adamo KB, Prud'homme D. The Need to Objectively Measure Physical
42 Activity During Pregnancy: Considerations for Clinical Research and Public Health Impact.
43 *Matern Child Health J* [Internet]. 2018;22(5):637–41. Available from:
44 <http://dx.doi.org/10.1007/s10995-018-2475-4>
45
- 46 109. Grym K, Niela-vilén H, Ekholm E, Hamari L, Azimi I, Rahmani A, et al. Feasibility of smart
47 wristbands for continuous monitoring during pregnancy and one month after birth. 2019;9:1–9.
48
- 49 110. Wear and Care Tips for Garmin Watches [Internet]. [cited 2019 Sep 8]. Available from:
50 [https://support.garmin.com/en-](https://support.garmin.com/en-US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn)
51 [US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn](https://support.garmin.com/en-US/?faq=yAgOpDYLCe4ftSa9k0dQx7&searchType=noProduct&source=grmn)
52
53
54
55
56
57
58
59
60

Table 1: Procedures and measurements used in the FitMum study


| Visit number | Visit 1 Screening and baseline testing | E-mail Randomization | Visit 2 | Visit 3 | Visit 4 Delivery | Visit 5 | |
|--|---|-----------------------------|--------------------|--------------------|--------------------------|-----------------------------------|-------------------------------|
| Gestational age (week+days) | Max. 15+0 | One week after inclusion | Week 28+0- 6 | Week 34+0- 6 | Approximately week 40 | 7-14 days after delivery | One year after delivery |
| Ultrasound scan | x | | | | | | |
| Verbal information about study | x | | | | | | |
| Medical interview to assess in- and exclusion criteria | x | | | | | | |
| Demographic and anthropometric data | x | | | | | | |
| Medical history, concomitant disease, and previous medication | x | | | | | | |
| Medical history, PA level, demographic and anthropometric data of the participant's partner | x | | | | | | |
| Written informed consent | x | | | | | | |
| Activity tracker and associated oral and written information | x | | | | | | |
| Randomization | | x | | | | | |
| METHODOLOGY FOR OBTAINING ENDPOINTS | | | | | | | |
| Activity tracker | Continuously during the trial and one year after delivery | | | | | | |
| Maternal body weight | x | | x | x | x | x | Six times at home |

| | | | | | | | |
|---|---|--|---|---|---|---|------------------------------|
| | | | | | | | during postpartum |
| Doubly labelled water | | | x | | | | |
| Questionnaires: PPAQ-DK, SF-36, PSQI, P-ESES, BREQ-2, sickness absence + pelvic and low back pain | x | | x | x | | | x |
| Maternal blood samples | x | | x | x | x | | |
| Paternal blood sample | | | | | x | | |
| Umbilical cord blood sample | | | | | x | | |
| Placenta samples | | | | | x | | |
| DXA-scan | | | | | | x | |
| Breast milk sample | | | | | | x | |
| Qualitative interview | x | | | x | | | x |
| Observation and autodocumentation | | | | | | | Recurring |
| ASQ-3 | | | | | | | x |
| Growth assessment at general practitioner | | | | | | | 5 weeks, and 5 and 12 months |
| Parental mental well-being questionnaire | | | | | | | 6-8 weeks postpartum |
| Seven-day child accelerometer | | | | | | | x |
| SAFETY | | | | | | | |
| Record adverse events | | | x | x | | | |
| Symphysis-fundal height | | | x | x | | | |

ASQ-3: Ages and Stages Questionnaire 3, BREQ-2: Behavioural Regulations Exercise Questionnaire, DXA: Dual-energy X-ray absorptiometry, P-ESES: Pregnancy Exercise Self-efficacy Scale, PPAQ-DK: Pregnancy PA Questionnaire (Danish version), PSQI: Pittsburgh Sleep Quality Index, SF-36: The Medical Outcomes Study Short Form 36.

Figure legends

Figure 1: Flow diagram of the FitMum randomized controlled trial

Figure 1: Flow diagram of the FitMum randomized controlled trial.



Informeret samtykke til deltagelse i et sundhedsvidenskabeligt forskningsprojekt

Forskningsprojektets titel: FitMum

Erklæring fra projektdeltageren:

Jeg har fået skriftlig og mundtlig information og ved nok om formål, metode, fordele og ulemper til at sige ja til at deltage i FitMum.

Jeg ved, at det er frivilligt at deltage, og at jeg altid kan trække mit samtykke tilbage, uden at det vil få konsekvenser for mit videre graviditets-, fødsels- og barselsforløb på Nordsjællands Hospital.

Jeg giver samtykke til at deltage i forskningsprojektet, og har fået en kopi af dette samtykkeark samt en kopi af den skriftlige information om projektet til eget brug.

Navn: _____

E-mail: _____

Telefonnummer: _____

Dato: _____ Underskrift: _____

Ønsker du at blive informeret om forskningsprojektets resultater samt eventuelle konsekvenser for dig?

Ja (sæt x) Nej (sæt x)

Ønsker du at blive informeret om væsentlige helbredsmæssige fund hos dig?

Ja (sæt x) Nej (sæt x)

Erklæring fra den, der afgiver information:

Jeg erklærer, at projektdeltageren har modtaget mundtlig og skriftlig information om projektet.

Efter min overbevisning er der givet tilstrækkelig information til, at der kan træffes beslutning om deltagelse i projektet.

Navnet på den, der har afgivet information: _____

Dato: _____ Underskrift: _____



**Informeret samtykke fra forældremyndighedsindehaver(e) til barns deltagelse
i et sundhedsvidenskabeligt forskningsprojekt
samt
informeret samtykke fra biologisk faders deltagelse
i et sundhedsvidenskabeligt forskningsprojekt**

Forskningsprojektets titel: FitMum

Erklæring fra indehaver(e) af forældremyndigheden til barns deltagelse:

Jeg/vi har fået skriftlig og mundtlig information og ved nok om formål, metode, fordele og ulemper til at give mit/vores samtykke til mit/vores barns deltagelse i FitMum. Jeg/vi ved, at det er frivilligt at deltage, og at jeg/vi altid kan trække mit/vores samtykke tilbage, uden at det vil få konsekvenser for det videre graviditets-, fødsels- og barselsforløb på Nordsjællands Hospital.

Jeg/vi giver samtykke til, at mit/vores endnu unavngivne barn deltager i forskningsprojektet, og at der i forbindelse med fødslen udtages navlesnorsblod og moderkagevæv, der opbevares i en forskningsbiobank, samt at overskydende biologisk materiale overføres til en biobank til fremtidig forskning. Jeg/vi har fået en kopi af dette samtykkeark samt en kopi af den skriftlige information om projektet til eget brug.

Navnet på forældremyndighedsindehaver a: _____

Dato: _____ Underskrift: _____

Navnet på forældremyndighedsindehaver b: _____

Dato: _____ Underskrift: _____

Ønsker du/I at blive informeret om forskningsprojektets resultater samt eventuelle konsekvenser for dit/jeres barn?

Ja _____ (sæt x) Nej _____ (sæt x)

Ønsker du/I at blive informeret om væsentlige helbredsmæssige fund hos dit/jeres barn?

Ja _____ (sæt x) Nej _____ (sæt x)

Erklæring fra biologisk fader til egen deltagelse:

Jeg (biologisk fader) har fået skriftlig og mundtlig information og ved nok om formål, metode, fordele og ulemper til at give mit samtykke til at deltage i FitMum.

Jeg ved, at det er frivilligt at deltage, og at jeg altid kan trække mit samtykke tilbage, uden at det vil få konsekvenser for det videre graviditets-, fødsels- og barselsforløb på Nordsjællands Hospital.

Jeg (biologisk fader) giver samtykke til at deltage i forskningsprojektet og til, at mit biologiske materiale (blod) opbevares i en forskningsbiobank, samt at overskydende biologisk materiale (blod) overføres til en biobank til fremtidig forskning. Jeg har fået en kopi af dette samtykkeark samt en kopi af den skriftlige information om projektet til eget brug.

Navnet på den biologiske fader: _____

Dato: _____ Underskrift: _____

Ønsker du (biologisk fader) at blive informeret om forskningsprojektets resultater samt eventuelle konsekvenser for dig?

Ja _____ (sæt x) Nej _____ (sæt x)

Ønsker du (biologisk fader) at blive informeret om væsentlige helbredsmæssige fund hos dig?

Ja _____ (sæt x) Nej _____ (sæt x)

Erklæring fra den, der afgiver information:

Jeg erklærer, at forældremyndighedsindehaver(e) har modtaget mundtlig og skriftlig information om projektet.

Efter min overbevisning er der givet tilstrækkelig information til, at forældremyndighedsindehaver(e) kan træffe beslutning om henholdsvis dit/deres barns og faderens deltagelse i projektet.

Navnet på den, der har afgivet information: _____

Dato: _____ Underskrift: _____



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

NA= not applicable

| Section/item | Item No | Description | Addressed on page number |
|-----------------------------------|---------|--|--------------------------|
| Administrative information | | | |
| Title | 1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | 2a | Trial identifier and registry name. If not yet registered, name of intended registry | 3 |
| | 2b | All items from the World Health Organization Trial Registration Data Set | NA |
| Protocol version | 3 | Date and version identifier | 3 |
| Funding | 4 | Sources and types of financial, material, and other support | 14 |
| Roles and responsibilities | 5a | Names, affiliations, and roles of protocol contributors | 1 & 14 |
| | 5b | Name and contact information for the trial sponsor | 14 |
| | 5c | Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities | NA |
| | 5d | Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) | 14 |

Introduction

| | | | |
|--------------------------|----|---|--------|
| Background and rationale | 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | 4&5 |
| | 6b | Explanation for choice of comparators | 4&5 |
| Objectives | 7 | Specific objectives or hypotheses | 5 |
| Trial design | 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) | 5 & 12 |

Methods: Participants, interventions, and outcomes

| | | | |
|----------------------|-----|--|----------|
| Study setting | 9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained | 5 |
| Eligibility criteria | 10 | Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) | 5 |
| Interventions | 11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered | 7&8 |
| | 11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | 13 |
| | 11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) | 7,8 & 11 |
| | 11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | NA |

| | | | | |
|----|----------------------|----|--|-------|
| 1 | | | | |
| 2 | Outcomes | 12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | 8 |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | Participant timeline | 13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | 23&24 |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | 12 |
| 20 | | | | |
| 21 | | | | |
| 22 | | | | |
| 23 | | | | |
| 24 | | | | |
| 25 | | | | |
| 26 | Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size | 5&6 |
| 27 | | | | |
| 28 | | | | |

Methods: Assignment of interventions (for controlled trials)

Allocation:

| | | | | |
|----|----------------------------------|-----|--|---|
| 31 | | | | |
| 32 | | | | |
| 33 | Sequence generation | 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | 6 |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | Allocation concealment mechanism | 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | 6 |
| 45 | | | | |
| 46 | | | | |
| 47 | | | | |
| 48 | | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Implementation | 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | 6 |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | Blinding (masking) | 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | 6 |
| 56 | | | | |
| 57 | | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

- 1
2 17b If blinded, circumstances under which unblinding 6
3 is permissible, and procedure for revealing a
4 participant's allocated intervention during the trial
5

6 **Methods: Data collection, management, and analysis**
7

- 8 Data collection 18a Plans for assessment and collection of outcome, 8-11
9 methods baseline, and other trial data, including any
10 related processes to promote data quality (eg,
11 duplicate measurements, training of assessors)
12 and a description of study instruments (eg,
13 questionnaires, laboratory tests) along with their
14 reliability and validity, if known. Reference to
15 where data collection forms can be found, if not
16 in the protocol
17
18
19
20 18b Plans to promote participant retention and NA
21 complete follow-up, including list of any outcome
22 data to be collected for participants who
23 discontinue or deviate from intervention protocols
24
25
26 Data management 19 Plans for data entry, coding, security, and 11
27 storage, including any related processes to
28 promote data quality (eg, double data entry;
29 range checks for data values). Reference to
30 where details of data management procedures
31 can be found, if not in the protocol
32
33
34 Statistical methods 20a Statistical methods for analysing primary and 12
35 secondary outcomes. Reference to where other
36 details of the statistical analysis plan can be
37 found, if not in the protocol
38
39
40 20b Methods for any additional analyses (eg, 12
41 subgroup and adjusted analyses)
42
43 20c Definition of analysis population relating to 12
44 protocol non-adherence (eg, as randomised
45 analysis), and any statistical methods to handle
46 missing data (eg, multiple imputation)
47
48

49 **Methods: Monitoring**

- 50
51 Data monitoring 21a Composition of data monitoring committee NA
52 (DMC); summary of its role and reporting
53 structure; statement of whether it is independent
54 from the sponsor and competing interests; and
55 reference to where further details about its
56 charter can be found, if not in the protocol.
57 Alternatively, an explanation of why a DMC is not
58 needed
59
60

| | | | |
|----|---------------------------------|-----|--|
| 1 | | | |
| 2 | | 21b | Description of any interim analyses and stopping |
| 3 | | | guidelines, including who will have access to |
| 4 | | | these interim results and make the final decision |
| 5 | | | to terminate the trial |
| 6 | | | |
| 7 | Harms | 22 | Plans for collecting, assessing, reporting, and |
| 8 | | | managing solicited and spontaneously reported |
| 9 | | | adverse events and other unintended effects of |
| 10 | | | trial interventions or trial conduct |
| 11 | | | |
| 12 | | | |
| 13 | Auditing | 23 | Frequency and procedures for auditing trial |
| 14 | | | conduct, if any, and whether the process will be |
| 15 | | | independent from investigators and the sponsor |
| 16 | | | |
| 17 | | | |
| 18 | Ethics and dissemination | | |
| 19 | | | |
| 20 | Research ethics | 24 | Plans for seeking research ethics |
| 21 | approval | | committee/institutional review board (REC/IRB) |
| 22 | | | approval |
| 23 | | | |
| 24 | Protocol | 25 | Plans for communicating important protocol |
| 25 | amendments | | modifications (eg, changes to eligibility criteria, |
| 26 | | | outcomes, analyses) to relevant parties (eg, |
| 27 | | | investigators, REC/IRBs, trial participants, trial |
| 28 | | | registries, journals, regulators) |
| 29 | | | |
| 30 | | | |
| 31 | Consent or assent | 26a | Who will obtain informed consent or assent from |
| 32 | | | potential trial participants or authorised |
| 33 | | | surrogates, and how (see Item 32) |
| 34 | | | |
| 35 | | | |
| 36 | | 26b | Additional consent provisions for collection and |
| 37 | | | use of participant data and biological specimens |
| 38 | | | in ancillary studies, if applicable |
| 39 | | | |
| 40 | Confidentiality | 27 | How personal information about potential and |
| 41 | | | enrolled participants will be collected, shared, |
| 42 | | | and maintained in order to protect confidentiality |
| 43 | | | before, during, and after the trial |
| 44 | | | |
| 45 | | | |
| 46 | Declaration of | 28 | Financial and other competing interests for |
| 47 | interests | | principal investigators for the overall trial and |
| 48 | | | each study site |
| 49 | | | |
| 50 | Access to data | 29 | Statement of who will have access to the final |
| 51 | | | trial dataset, and disclosure of contractual |
| 52 | | | agreements that limit such access for |
| 53 | | | investigators |
| 54 | | | |
| 55 | | | |
| 56 | Ancillary and post- | 30 | Provisions, if any, for ancillary and post-trial care, |
| 57 | trial care | | and for compensation to those who suffer harm |
| 58 | | | from trial participation |
| 59 | | | |
| 60 | | | |

| | | | |
|----|-------------------|-----|---|
| 1 | | | |
| 2 | Dissemination | 31a | Plans for investigators and sponsor to |
| 3 | policy | | communicate trial results to participants, |
| 4 | | | healthcare professionals, the public, and other |
| 5 | | | relevant groups (eg, via publication, reporting in |
| 6 | | | results databases, or other data sharing |
| 7 | | | arrangements), including any publication |
| 8 | | | restrictions |
| 9 | | | |
| 10 | | | |
| 11 | | 31b | Authorship eligibility guidelines and any intended |
| 12 | | | use of professional writers |
| 13 | | | |
| 14 | | 31c | Plans, if any, for granting public access to the full |
| 15 | | | protocol, participant-level dataset, and statistical |
| 16 | | | code |
| 17 | | | |
| 18 | | | |
| 19 | Appendices | | |
| 20 | | | |
| 21 | Informed consent | 32 | Model consent form and other related |
| 22 | materials | | documentation given to participants and |
| 23 | | | authorised surrogates |
| 24 | | | |
| 25 | Biological | 33 | Plans for collection, laboratory evaluation, and |
| 26 | specimens | | storage of biological specimens for genetic or |
| 27 | | | molecular analysis in the current trial and for |
| 28 | | | future use in ancillary studies, if applicable |
| 29 | | | |
| 30 | | | |

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.